<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Adalimumab (including biosimilars): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Adalimumab (including biosimilars): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Adalimumab (including biosimilars): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8583" href="/d/html/8583.html" rel="external">see "Adalimumab (including biosimilars): Drug information"</a> and <a class="drug drug_patient" data-topicid="12437" href="/d/html/12437.html" rel="external">see "Adalimumab (including biosimilars): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708607"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Serious infections:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Patients treated with adalimumab are at increased risk of developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants, such as methotrexate or corticosteroids.</p>
<p style="text-indent:-2em;margin-left:2em;">Discontinue adalimumab if a patient develops a serious infection or sepsis. Reported infections include the following:</p>
<p style="text-indent:-2em;margin-left:4em;">Active tuberculosis (TB), including reactivation of latent TB. Patients with TB frequently have presented with disseminated or extrapulmonary disease. Test patients for latent TB before adalimumab use and during therapy. Initiate treatment for latent infection prior to adalimumab use.</p>
<p style="text-indent:-2em;margin-left:4em;">Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric antifungal therapy in patients at risk of invasive fungal infections who develop severe systemic illness.</p>
<p style="text-indent:-2em;margin-left:4em;">Bacterial, viral, and other infections caused by opportunistic pathogens, including Legionella and Listeria.</p>
<p style="text-indent:-2em;margin-left:2em;">Carefully consider the risks and benefits of treatment with adalimumab prior to initiating therapy in patients with chronic or recurrent infection.</p>
<p style="text-indent:-2em;margin-left:2em;">Monitor patients closely for the development of signs and symptoms of infection during and after treatment with adalimumab, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Malignancy:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Lymphoma and other malignancies, some fatal, have been reported in children and adolescents treated with tumor necrosis factor (TNF)–blockers, including adalimumab. Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF-blockers, including adalimumab. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF-blocker cases have occurred in patients with Crohn disease or ulcerative colitis and the majority were in adolescent and young adult males. Almost all these patients had received treatment with azathioprine or 6-mercaptopurine concomitantly with a TNF-blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is related to use of a TNF-blocker or a TNF-blocker in combination with these other immunosuppressants.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F130499"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Abrilada;</li>
<li>Amjevita;</li>
<li>Cyltezo;</li>
<li>Cyltezo-CD/UC/HS Starter;</li>
<li>Cyltezo-Psoriasis Starter;</li>
<li>Hadlima;</li>
<li>Hadlima PushTouch;</li>
<li>Hulio;</li>
<li>Humira;</li>
<li>Humira Pediatric Crohns Start;</li>
<li>Humira Pen;</li>
<li>Humira Pen-CD/UC/HS Starter;</li>
<li>Humira Pen-Pediatric UC Start;</li>
<li>Humira Pen-Ps/UV/Adol HS Start;</li>
<li>Humira Pen-Psor/Uveit Starter;</li>
<li>Hyrimoz;</li>
<li>Hyrimoz-Crohns/UC Starter;</li>
<li>Hyrimoz-Plaque Psoriasis Start;</li>
<li>Idacio;</li>
<li>Idacio for Crohns Disease/UC;</li>
<li>Idacio for Plaque Psoriasis;</li>
<li>Yuflyma;</li>
<li>Yuflyma 1-Pen Kit;</li>
<li>Yuflyma 2-Pen Kit;</li>
<li>Yuflyma 2-Syringe Kit;</li>
<li>Yuflyma-CD/UC/HS Starter;</li>
<li>Yusimry</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52865555"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Abrilada;</li>
<li>Amgevita;</li>
<li>Amgevita SureClick;</li>
<li>Hadlima;</li>
<li>Hadlima PushTouch;</li>
<li>Hulio;</li>
<li>Humira;</li>
<li>Hyrimoz;</li>
<li>Idacio;</li>
<li>Simlandi;</li>
<li>Yuflyma</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F996315"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antirheumatic, Disease Modifying</span>;</li>
<li>
<span class="list-set-name">Gastrointestinal Agent, Miscellaneous</span>;</li>
<li>
<span class="list-set-name">Monoclonal Antibody</span>;</li>
<li>
<span class="list-set-name">Tumor Necrosis Factor (TNF) Blocking Agent</span></li></ul></div>
<div class="block dop drugH1Div" id="F5737985"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information: </b>In the United States, Amjevita (adalimumab-atto) has been approved as a biosimilar to Humira (adalimumab). In Canada, Abrilada, Amgevita, Hadlima, Hulio, Hyrimoz, Idacio, Simlandi, and Yuflyma are also approved as biosimilars to Humira; refer to Canadian product monograph(s) for biosimilar-specific indication details. Approved ages and uses may vary (consult product labeling).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="59567581-c67d-4a97-908a-59b5a164c324">Crohn disease, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Crohn disease, moderate to severe:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">17 kg to &lt;40 kg: SUBQ:</p>
<p style="text-indent:-2em;margin-left:8em;">Initial: 80 mg on day 1, then 40 mg administered 2 weeks later (day 15).</p>
<p style="text-indent:-2em;margin-left:8em;">Maintenance (beginning day 29): 20 mg every other week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>). Patients who continue to experience flares after 12 weeks of therapy may benefit from weekly dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26950307','lexi-content-ref-22562021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26950307','lexi-content-ref-22562021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">≥40 kg: SUBQ:</p>
<p style="text-indent:-2em;margin-left:8em;">Initial: 160 mg (administered on day 1 <b>or</b> split and administered over 2 consecutive days), then 80 mg administered 2 weeks later (day 15).</p>
<p style="text-indent:-2em;margin-left:8em;">Maintenance (beginning day 29): 40 mg every other week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>). Weekly dosing should be considered for patients with loss of response or low trough concentrations (&lt;7.5 mcg/mL) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26950307','lexi-content-ref-33026087','lexi-content-ref-22562021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26950307','lexi-content-ref-33026087','lexi-content-ref-22562021'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a1a5c771-d06c-4f42-a40c-2a0c6db81cba">Hidradenitis suppurativa</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hidradenitis suppurativa:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">30 to &lt;60 kg: SUBQ:</p>
<p style="text-indent:-2em;margin-left:8em;">Initial: 80 mg on day 1.</p>
<p style="text-indent:-2em;margin-left:8em;">Maintenance (beginning day 8): 40 mg every other week.</p>
<p style="text-indent:-2em;margin-left:6em;">≥60 kg: SUBQ:</p>
<p style="text-indent:-2em;margin-left:8em;">Initial: 160 mg (administered as full dose on day 1 <b>or</b> dose split and administered over 2 consecutive days), then 80 mg 2 weeks later (day 15).</p>
<p style="text-indent:-2em;margin-left:8em;">Maintenance (beginning day 29): 40 mg weekly or 80 mg every other week.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7bfa6a19-11be-4097-9456-7c7ce2ad756d">Juvenile idiopathic arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Juvenile idiopathic arthritis (JIA):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Fixed dosing:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥2 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">10 kg to &lt;15 kg: SUBQ: 10 mg every other week.</p>
<p style="text-indent:-2em;margin-left:8em;">15 to &lt;30 kg: SUBQ: 20 mg every other week.</p>
<p style="text-indent:-2em;margin-left:8em;">≥30 kg: SUBQ: 40 mg every other week.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>BSA-directed dosing</i>: <b>Note</b>: Dosing based on trials performed with Humira product.</p>
<p style="text-indent:-2em;margin-left:6em;">Children 2 to &lt;4 years: SUBQ: 24 mg/m<sup>2</sup>/dose every other week; maximum dose: 20 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Humira.3','lexi-content-ref-24487484']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Humira.3','lexi-content-ref-24487484'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents 4 to 17 years: SUBQ: 24 mg/m<sup>2</sup>/dose every other week; maximum dose: 40 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26223543','lexi-content-ref-Humira.3','lexi-content-ref-18716298']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26223543','lexi-content-ref-Humira.3','lexi-content-ref-18716298'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3b817b24-f4bd-4321-911a-fe2fc5fe6edc">Ulcerative colitis; moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ulcerative colitis; moderate to severe:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Fixed dosing:</i> Children ≥5 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">20 to &lt;40 kg: SUBQ:</p>
<p style="text-indent:-2em;margin-left:8em;">Initial: 80 mg on day 1, then 40 mg administered weekly for 2 weeks (a dose on day 8 and day 15).</p>
<p style="text-indent:-2em;margin-left:8em;">Maintenance (beginning day 29): 40 mg every other week or 20 mg every week.</p>
<p style="text-indent:-2em;margin-left:6em;">≥40 kg: SUBQ:</p>
<p style="text-indent:-2em;margin-left:8em;">Initial: 160 mg on day 1 (administered as full dose on day 1 <b>or</b> dose split and administered over 2 consecutive days), then 80 mg administered weekly for 2 weeks (a dose on day 8 and day 15).</p>
<p style="text-indent:-2em;margin-left:8em;">Maintenance (beginning day 29): 80 mg every other week or 40 mg every week.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>BSA-directed dosing:</i> Children and Adolescents: SUBQ: Initial: 92 mg/m<sup>2</sup> (maximum dose: 160 mg/dose), then 46 mg/m<sup>2</sup> (maximum dose: 80 mg/dose) 2 weeks later, then on day 29, begin maintenance therapy: 23 mg/m<sup>2</sup> every other week (maximum dose: 40 mg/dose) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30044357']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30044357'])">Ref</a></span>). <b>Note:</b> Trials performed with Humira product.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="571054ef-6fb3-4677-9101-4840672bf0aa">Uveitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Uveitis (noninfectious intermediate, posterior, and panuveitis):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Fixed dosing</i>: Children ≥2 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">10 kg to &lt;15 kg: SUBQ: 10 mg every other week.</p>
<p style="text-indent:-2em;margin-left:6em;">15 to &lt;30 kg: SUBQ: 20 mg every other week.</p>
<p style="text-indent:-2em;margin-left:6em;">≥30 kg: SUBQ: 40 mg every other week.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>BSA-directed dosing:</i> Children ≥4 years and Adolescents: SUBQ: 24 or 40 mg/m<sup>2</sup>/dose every 2 weeks; maximum dose 40 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17556427','lexi-content-ref-21452272']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17556427','lexi-content-ref-21452272'])">Ref</a></span>). Dosing based on one prospective trial comparing 24 mg/m<sup>2</sup>/dose every 2 weeks of adalimumab (n=16, ages 6 to 12 years) to infliximab (n=17, ages 5 to 13 years) and on a retrospective trial of biologic response modifiers, including 5 patients who received adalimumab at 40 mg/m<sup>2</sup>/dose every 2 weeks. <b>Note:</b> Trials performed with Humira product.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51011067"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51011068"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F130502"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8583" href="/d/html/8583.html" rel="external">see "Adalimumab (including biosimilars): Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: </b>Before therapy initiation, ensure appropriate immunization (if possible) and screen for active or latent infections. Treatment of tuberculosis (TB) infection (latent TB) is required before starting adalimumab. Avoid use in patients with severe active infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22473917','lexi-content-ref-21339216','lexi-content-ref-Lok.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22473917','lexi-content-ref-21339216','lexi-content-ref-Lok.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> In the United States, Abrilada (adalimumab-afzb), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm), Hadlima (adalimumab-bwwd), Hulio (adalimumab-fkjp), Hyrimoz (adalimumab-adaz), Idacio (adalimumab-aacf), Yuflyma (adalimumab-aaty), and Yusimry (adalimumab-aqvh) have been approved as biosimilars to Humira (adalimumab). In Canada, Abrilada, Amgevita, Hadlima, Hulio, Hyrimoz, Idacio, Simlandi, and Yuflyma are also approved as biosimilars to Humira; refer to Canadian product monograph(s) for biosimilar-specific indication details.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1f6d45a1-20a1-430e-8557-bef8c100388b">Axial spondyloarthritis, including ankylosing spondylitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Axial spondyloarthritis, including ankylosing spondylitis (Humira and adalimumab biosimilars):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Reserve for patients who do not have an adequate response to nonsteroidal anti-inflammatory drugs (NSAIDs); may continue NSAIDs and/or analgesics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31436026','lexi-content-ref-22772328']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31436026','lexi-content-ref-22772328'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ:</b> 40 mg every other week.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c67c5889-0329-4697-8e94-8d70bc250092">Crohn disease, moderate to severe, induction and maintenance of remission</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Crohn disease, moderate to severe, induction and maintenance of remission (Humira and adalimumab biosimilars):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Combination therapy with an immunomodulator (ie, thiopurine or methotrexate) is generally preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29610508','lexi-content-ref-34051983']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29610508','lexi-content-ref-34051983'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Initial: SUBQ: </b>160 mg (given over 1 or 2 days), then 80 mg 2 weeks later (day 15). <b>Note: </b>If switching from another anti-tumor necrosis factor agent, may use this induction regimen.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Maintenance: SUBQ: </b>40 mg every other week beginning day 29.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="efb110b3-f86c-41d9-bfb1-b685525fd803">Hidradenitis suppurativa, moderate to severe, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hidradenitis suppurativa, moderate to severe, refractory (Humira and adalimumab biosimilars):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Initial:</b>
<b>SUBQ: </b>160 mg (given over 1 or 2 days), then 80 mg 2 weeks later (day 15).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Maintenance: SUBQ:</b> 40 mg every week beginning day 29 <b>or</b> 80 mg every other week beginning day 29 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27518661','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27518661','lexi-content-ref-manu.1'])">Ref</a></span>). <b>Note:</b> 40 mg every week regimen has been more extensively studied and is therefore preferred by some experts (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Ingram.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Ingram.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4f086440-d826-408b-a554-385b730eadc9">Nonradiographic axial spondyloarthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nonradiographic axial spondyloarthritis (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Reserve for patients who do not have an adequate response to NSAIDs; may continue NSAIDs and/or analgesics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31436026','lexi-content-ref-22772328']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31436026','lexi-content-ref-22772328'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ:</b> 40 mg every other week.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="497b8a69-5eed-404f-b584-b9b980ba3248">Peripheral spondyloarthritis, nonpsoriatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peripheral spondyloarthritis, nonpsoriatic (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>May continue methotrexate, other nonbiologic DMARDs, corticosteroids, NSAIDs, and/or analgesics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25545240','lexi-content-ref-23139265']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25545240','lexi-content-ref-23139265'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ:</b> 40 mg every other week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25545240','lexi-content-ref-23139265']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25545240','lexi-content-ref-23139265'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="46fc9b4b-22ea-4096-b090-0ebc9997e04a">Plaque psoriasis, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Plaque psoriasis, moderate to severe (Humira and adalimumab biosimilars):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Generally used as systemic monotherapy; may continue adjuvant topical therapies (eg, emollients, corticosteroids) as needed. A clinician experienced with use of adalimumab for plaque psoriasis should be involved in treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Initial: SUBQ: </b>80 mg as a single dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Maintenance: SUBQ: </b>40 mg every other week beginning 1 week after initial dose. <b>Note: </b>Some patients may require 40 mg every week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30772098']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30772098'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1bfcea56-f4f1-4785-9277-8d2c90e99a99">Psoriatic arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Psoriatic arthritis (Humira and adalimumab biosimilars):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>May continue methotrexate, other nonbiologic DMARDs, corticosteroids, NSAIDs, and/or analgesics.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ:</b> 40 mg every other week.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="32775de1-c27b-4d28-84e6-04adfdee9a40">Rheumatoid arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rheumatoid arthritis (Humira and adalimumab biosimilars):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note</b>: For use as an alternative to methotrexate in disease-modifying antirheumatic drug (DMARD)–naive patients with moderate to high disease activity, or as adjunctive therapy in patients who have not met treatment goals despite maximally tolerated methotrexate therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34101387']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34101387'])">Ref</a></span>). May use in combination with other nonbiologic DMARDs, glucocorticoids, NSAIDs, and/or analgesics. A clinician experienced with use of adalimumab for rheumatoid arthritis should be involved in treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ:</b> Initial: 40 mg every other week; for select patients with an inadequate response, may increase dose to 40 mg every week or 80 mg every other week.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="45ccdfdc-12e9-4566-918e-b18caa15a979">Sarcoidosis, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sarcoidosis, refractory (adjunctive agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For use as an adjunctive agent in patients in whom treatment goals have not been met despite glucocorticoids and other immunosuppressants (eg, methotrexate) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25078637','lexi-content-ref-34140301','lexi-content-ref-24751453']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25078637','lexi-content-ref-34140301','lexi-content-ref-24751453'])">Ref</a></span>). A clinician experienced with use of adalimumab should be involved in treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Initial: SUBQ: </b>The optimal dosing strategy is not known; one example of an initial regimen is 40 to 120 mg on week 0, 40 to 80 mg on week 1, and 40 mg on week 2 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27215507','lexi-content-ref-25078637','lexi-content-ref-23276549']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27215507','lexi-content-ref-25078637','lexi-content-ref-23276549'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Maintenance: SUBQ:</b> 40 mg every 1 to 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27215507','lexi-content-ref-25078637','lexi-content-ref-34140301','lexi-content-ref-23276549']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27215507','lexi-content-ref-25078637','lexi-content-ref-34140301','lexi-content-ref-23276549'])">Ref</a></span>). The optimal frequency and duration of therapy are not known and must be individualized based on response; after a stable response is achieved (eg, after 6 months), one option is to gradually prolong the dosing interval (eg, to every 2 weeks) and discontinue after 3 months if response remains adequate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25078637','lexi-content-ref-34143362']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25078637','lexi-content-ref-34143362'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="56f84580-0f24-42fe-ac3a-5445fed1b221">Ulcerative colitis, moderate to severe, induction and maintenance of remission</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ulcerative colitis, moderate to severe,</b>
<b>induction and maintenance of remission (Humira and adalimumab biosimilars):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Initial: SUBQ: </b>160 mg (given over 1 or 2 days), then 80 mg 2 weeks later (day 15).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Maintenance: SUBQ</b>: 40 mg every other week beginning day 29. If a disease flare occurs, some experts increase to 40 mg every week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-A-Rahim.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-A-Rahim.1','lexi-content-ref-manu.1'])">Ref</a></span>). <b>Note:</b> Only continue maintenance treatment in patients demonstrating clinical remission by 8 weeks (day 57) of therapy.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="241167ae-37ec-4f5e-83cd-2298bcb5b902">Uveitis, noninfectious</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Uveitis, noninfectious (Humira and adalimumab biosimilars [except Yuflyma]):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Generally reserved for patients with an incomplete response to first-line agents and ≥1 other systemic therapies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Rosenbaum.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Rosenbaum.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Initial: SUBQ:</b> 80 mg as a single dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Maintenance: SUBQ:</b> 40 mg every other week beginning 1 week after initial dose.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991104"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Theoretically, adalimumab’s large molecular weight (148,000 daltons) precludes the drug from being efficiently filtered at the glomerulus or by dialysis filters; hence, dose adjustments for kidney dysfunction and/or renal replacement therapies should generally be unnecessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b>
<b>SUBQ</b>
<b>:</b> No dosage adjustment necessary for any degree of kidney dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35546331','lexi-content-ref-17337474','lexi-content-ref-22807318','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35546331','lexi-content-ref-17337474','lexi-content-ref-22807318','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m</b>
<b>
<sup>2</sup></b>
<b>):</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Younger patients (&lt;55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>): <b>SUBQ</b>
<b>:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be significantly dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>): <b>SUBQ</b>
<b>:</b> No dosage adjustment or supplemental dose necessary; patients with end-stage kidney disease (ESKD) often suffer from impaired immune function, monitor closely for infection during adalimumab therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29447652','lexi-content-ref-25916786','lexi-content-ref-22807318','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29447652','lexi-content-ref-25916786','lexi-content-ref-22807318','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis: </b> Unlikely to be significantly dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>): <b>SUBQ</b>
<b>:</b> No dosage adjustment necessary; patients with ESKD often suffer from impaired immune function; monitor closely for infection during adalimumab therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20340019','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20340019','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b>
<b>SUBQ</b>
<b>:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b>
<b>SUBQ</b>
<b>:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988402"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block arsc drugH1Div" id="F57409638"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Autoimmune disorder</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Antibody development</b> may occur with the use of tumor necrosis factor alpha inhibitors (TNFai), including adalimumab. Most frequently, autoantibodies include anti-nuclear antibody (ANA) and anti-double stranded DNA (dsDNA); less frequently, anti-ENA, anti-histone Ab, and anti-cardiolipin Ab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33747126','lexi-content-ref-25110258','lexi-content-ref-16439435']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33747126','lexi-content-ref-25110258','lexi-content-ref-16439435'])">Ref</a></span>). Frequency of autoantibody development varies depending on underlying disease, specific TNFai medication, and the duration of use; the clinical significance of asymptomatic antibody positivity is unclear (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25110258']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25110258'])">Ref</a></span>). Antibody positivity may rarely result in the development of an autoimmune disorder, such as <b>lupus-like syndrome</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22562972','lexi-content-ref-25110258','lexi-content-ref-26768759','lexi-content-ref-16439435']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22562972','lexi-content-ref-25110258','lexi-content-ref-26768759','lexi-content-ref-16439435'])">Ref</a></span>). Symptoms may include <b>arthralgia</b>, myalgia, mucocutaneous symptoms (eg, <b>skin rash</b>), cytopenia, fatigue, <b>fever</b>, serositis and kidney injury (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33747126','lexi-content-ref-25110258']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33747126','lexi-content-ref-25110258'])">Ref</a></span>). Development of an autoimmune disorder is associated with a poor treatment response of the original disease to TNFai therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33747126']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33747126'])">Ref</a></span>). It is unclear if the development of an autoimmune disorder is a TNFai class effect; several reports of rechallenge with the same TNFai or a different TNFai after treatment of the initial autoimmune disorder did not result in a recurrence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25110258']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25110258'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Unknown; Postulated mechanisms include bystander activation of autoreactive lymphocytes due to drug-specific immunity, nonspecific activation of lymphocytes, direct cytotoxicity with release of autoantigens, and disruption of central T-cell tolerance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15767026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15767026'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; ranged from 5 weeks to 2 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25739794']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25739794'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Longer disease duration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33747126']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33747126'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33747126','lexi-content-ref-12851868','lexi-content-ref-24185311']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33747126','lexi-content-ref-12851868','lexi-content-ref-24185311'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Ulcerative colitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33747126']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33747126'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Demyelinating disease</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">New-onset or exacerbation of central and peripheral nervous system <b>demyelinating disease</b>, such as <b>multiple sclerosis</b>, <b>optic neuritis</b>, acute transverse myelitis, <b>Guillain-Barré syndrome</b>, and chronic inflammatory demyelinating polyneuropathy may occur with tumor necrosis factor alpha inhibitors (TNFai), although causality has not been proven (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34557936','lexi-content-ref-31921355','lexi-content-ref-33945946','lexi-content-ref-32421186','lexi-content-ref-19854301','lexi-content-ref-23287362','lexi-content-ref-33863839']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34557936','lexi-content-ref-31921355','lexi-content-ref-33945946','lexi-content-ref-32421186','lexi-content-ref-19854301','lexi-content-ref-23287362','lexi-content-ref-33863839'])">Ref</a></span>). Symptomatic CNS demyelination associated with TNFai may be monophasic and/or clinically isolated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31845616']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31845616'])">Ref</a></span>). Partial or complete resolution may occur after discontinuation of TNFai (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11762947']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11762947'])">Ref</a></span>); however, approximately one-third of TNFai associated demyelinating episodes evolve into clinically definite multiple sclerosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30767720']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30767720'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Unknown; several mechanisms have been postulated, including the following: May trigger CNS demyelination directly by immune activation in genetically and/or immunologically predisposed individuals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31845616']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31845616'])">Ref</a></span>); may inhibit remyelination via TNF type-2 receptor (TNRF2) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9345421']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9345421'])">Ref</a></span>); may increase ingress of auto-reactive T cells in the CNS; may alter downstream cytokine responses; may neutralize TNF systemically but not within the CNS, creating an artificially high local concentration of brain TNF (known as sponge effect); may permit latent CNS viral infection; or may promote anti-drug antibodies and immune complexes that are contributory to demyelination events (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28337644','lexi-content-ref-25169849']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28337644','lexi-content-ref-25169849'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; mean time of exposure to TNFai before onset of symptoms: 18 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28337644']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28337644'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting or recent onset central or peripheral nervous system demyelinating disease</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Dermatologic reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Various cutaneous eruptions have been reported, including <b>psoriasiform eruption</b> (either new-onset or exacerbation), hidradenitis suppurativa, <b>lupus-like syndrome</b>, <b>eczematous rash</b>, <b>pustular rash</b>, <b>lichenoid eruption</b>, and <b>hypersensitivity angiitis </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26312693','lexi-content-ref-29859201','lexi-content-ref-21351201','lexi-content-ref-32527153','lexi-content-ref-26965410','lexi-content-ref-24697221','lexi-content-ref-32975341','lexi-content-ref-27777187','lexi-content-ref-25756476','lexi-content-ref-26422518','lexi-content-ref-30028008','lexi-content-ref-23453887','lexi-content-ref-19628303','lexi-content-ref-17632266','lexi-content-ref-29718343']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26312693','lexi-content-ref-29859201','lexi-content-ref-21351201','lexi-content-ref-32527153','lexi-content-ref-26965410','lexi-content-ref-24697221','lexi-content-ref-32975341','lexi-content-ref-27777187','lexi-content-ref-25756476','lexi-content-ref-26422518','lexi-content-ref-30028008','lexi-content-ref-23453887','lexi-content-ref-19628303','lexi-content-ref-17632266','lexi-content-ref-29718343'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Psoriasiform eruptions, lichenoid drug eruptions: Non–dose-related; possibly related to cytokine imbalance or imbalance between tumor necrosis factor (TNF)-alpha and interferon-alpha (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29869804','lexi-content-ref-22515220','lexi-content-ref-27777187']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29869804','lexi-content-ref-22515220','lexi-content-ref-27777187'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Psoriasiform eruptions: Delayed: Mean 15.6 ± 10.7 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33151572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33151572'])">Ref</a></span>). Hidradenitis suppurativa: Delayed; median 12 months (range: 1 to 72) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32135533']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32135533'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Adult females (psoriatic lesions) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32527153','lexi-content-ref-31093599']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32527153','lexi-content-ref-31093599'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Smoking (psoriatic lesions) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26235565']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26235565'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Males (palmoplantar pustulosis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29869804']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29869804'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Younger patients (&lt;40 years of age) (palmoplantar pustulosis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29869804']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29869804'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with inflammatory bowel disease compared to other inflammatory diseases (psoriasiform reactions more frequent and severe) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28218339']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28218339'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (hidradenitis suppurativa) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31290151']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31290151'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity data among TNFai in patients who develop psoriatic lesions are conflicting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33151572','lexi-content-ref-34402108','lexi-content-ref-28211161','lexi-content-ref-30028008','lexi-content-ref-34625145']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33151572','lexi-content-ref-34402108','lexi-content-ref-28211161','lexi-content-ref-30028008','lexi-content-ref-34625145'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Heart failure</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">New-onset <b>heart failure</b> (HF) and <b>worsening of heart failure</b> have been reported with tumor necrosis factor-alpha inhibitors (TNFai), including adalimumab; however, data are conflicting, and risk is unclear (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21328309']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21328309'])">Ref</a></span>). Rheumatoid arthritis (RA) may be a risk factor for HF development (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15692992']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15692992'])">Ref</a></span>). Some data suggest that TNFai may reduce the risk of HF in the RA population by improving inflammation, lowering disease activity, and improving surrogate markers of cardiovascular disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20038753','lexi-content-ref-34496051','lexi-content-ref-20472597']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20038753','lexi-content-ref-34496051','lexi-content-ref-20472597'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Not clearly established; postulated mechanisms include pro-inflammatory cytokine activation, accelerated atherosclerosis, and reduced physical activity related to the underlying rheumatologic disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24093840','lexi-content-ref-16981296']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24093840','lexi-content-ref-16981296'])">Ref</a></span>). "Reverse-signaling" may occur, leading to cardiotoxic effects; TNF on cardiomyocytes of the failing heart may act as receptors, activating intracellular signaling pathways, potentiating the toxic effect of the cytokine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10843670','lexi-content-ref-23557269','lexi-content-ref-29895751']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10843670','lexi-content-ref-23557269','lexi-content-ref-29895751'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; median 8.5 months (range: 5 to 17 months (data with infliximab) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12755552']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12755552'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting heart failure</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher disease activity (inflammation) (eg, disease activity score (DAS28), C-reactive protein, erythrocyte sedimentation rate) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24458537','lexi-content-ref-21216812','lexi-content-ref-25609412','lexi-content-ref-25776112']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24458537','lexi-content-ref-21216812','lexi-content-ref-25609412','lexi-content-ref-25776112'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatitis B virus reactivation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Reactivation of hepatitis B virus (HBV) may occur with immunosuppressive or biologic therapy, including tumor necrosis factor-alpha inhibitors (TNFai) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28219691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28219691'])">Ref</a></span>). <b>Reactivation of HBV</b> may occur in both patients who are HBsAg-positive and in patients who are HBsAg-negative/HBcAb-positive with detectable HBV DNA (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21719446']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21719446'])">Ref</a></span>). Criteria for HBV reactivation includes (1) a rise in HBV DNA compared to baseline (or an absolute level of HBV DNA when a baseline is unavailable) and (2) reverse seroconversion (seroreversion) from HBsAg negative to HBsAg positive for patients who are HBsAg-negative and anti-HBc–positive (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29405329']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29405329'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Inhibit stimulation of HBV specific T-lymphocytes, promoting reactivation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21719446']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21719446'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; 2 weeks after initiation, up to a year after discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28219691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28219691'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Males (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34427860','lexi-content-ref-28219691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34427860','lexi-content-ref-28219691'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34427860','lexi-content-ref-28219691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34427860','lexi-content-ref-28219691'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Presence of cirrhosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34427860','lexi-content-ref-28219691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34427860','lexi-content-ref-28219691'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• High baseline HBV-DNA level (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34427860','lexi-content-ref-28219691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34427860','lexi-content-ref-28219691'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• HBeAg or HBsAg seropositivity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34427860','lexi-content-ref-28219691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34427860','lexi-content-ref-28219691'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Absence of anti-HBs among patients with resolved HBV infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34427860']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34427860'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Chronic HBV (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28219691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28219691'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Non-A HBV genotype (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28219691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28219691'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hepatitis C, hepatitis D, or HIV co-infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28219691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28219691'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Adalimumab has been associated with <b>increased serum transaminases</b> and <b>hepatotoxicity </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32025603']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32025603'])">Ref</a></span>). <b>Cholestatic hepatitis</b>, <b>reactivation of hepatitis B virus</b>, and <b>autoimmune hepatitis</b> have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19593165','lexi-content-ref-30637218','lexi-content-ref-25431703','lexi-content-ref-23333219','lexi-content-ref-22205272','lexi-content-ref-24179620','lexi-content-ref-24244376','lexi-content-ref-26140007','lexi-content-ref-32025603']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19593165','lexi-content-ref-30637218','lexi-content-ref-25431703','lexi-content-ref-23333219','lexi-content-ref-22205272','lexi-content-ref-24179620','lexi-content-ref-24244376','lexi-content-ref-26140007','lexi-content-ref-32025603'])">Ref</a></span>). Elevated aminotransferases between 2 to 3 times the upper limit of normal may occur that are usually transient and asymptomatic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32025603','lexi-content-ref-25756190']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32025603','lexi-content-ref-25756190'])">Ref</a></span>). Resolution of symptoms in patients who develop an autoimmune hepatitis may require initiation of corticosteroid therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23333219','lexi-content-ref-22205272']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23333219','lexi-content-ref-22205272'])">Ref</a></span>). Immunomodulatory use, in particular methotrexate, may decrease the risk of hepatotoxicity associated with tumor necrosis factor-alpha inhibitors (TNFai) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25131534']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25131534'])">Ref</a></span>). Patients often tolerate a different TNFai (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25131534','lexi-content-ref-34487751','lexi-content-ref-19505409','lexi-content-ref-24707412','lexi-content-ref-22662786']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25131534','lexi-content-ref-34487751','lexi-content-ref-19505409','lexi-content-ref-24707412','lexi-content-ref-22662786'])">Ref</a></span>); although, hepatotoxicity may recur with an alternative agent in some cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26692395']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26692395'])">Ref</a></span>). Hepatotoxicity is more commonly associated with infliximab, as compared to adalimumab and other TNFai (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25131534','lexi-content-ref-28652663']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25131534','lexi-content-ref-28652663'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Unknown; idiosyncratic drug reaction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29564668']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29564668'])">Ref</a></span>), or autoimmunity due to development of autoantibodies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19593165']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19593165'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; ranges from 4 weeks to 52 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31870134','lexi-content-ref-23333219','lexi-content-ref-24707412']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31870134','lexi-content-ref-23333219','lexi-content-ref-24707412'])">Ref</a></span>). Autoimmune hepatitis has a longer latency period than non-immune cases (16 weeks vs 10 weeks, respectively) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23333219']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23333219'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Infection</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Tumor necrosis factor-alpha inhibitors (TNFai) may be associated with <b>infection</b> (including <b>serious infection</b>). In clinical trials, serious infections were numerically higher among patients treated with TNFai than among patients who received placebo. Meta-analyses and observational studies have reported inconsistency in risk. One study reported an increase in serious infection in patients treated with TNFai (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16705109']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16705109'])">Ref</a></span>). Another study found no increase in risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18753157']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18753157'])">Ref</a></span>). An observational study did not demonstrate an increased infection risk among patients receiving TNFai versus comparators (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22056398']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22056398'])">Ref</a></span>). Infections may present as disseminated (rather than local) disease. Active tuberculosis (including reactivation of latent tuberculosis), invasive fungal infection (including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, and pneumocystosis) and bacterial infection, viral infection, or other opportunistic infections (including legionellosis and listeriosis) have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; TNFa is important in the immune response against infections, suggesting that medications that inhibit TNFa may increase the risk of infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21328309']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21328309'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18753157']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18753157'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21791449']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21791449'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Chronic lung or kidney disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21791449']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21791449'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent immunosuppressants (eg, corticosteroids, methotrexate) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22056398','lexi-content-ref-30876964','lexi-content-ref-21791449','lexi-content-ref-16447241']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22056398','lexi-content-ref-30876964','lexi-content-ref-21791449','lexi-content-ref-16447241'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of an opportunistic infection</p>
<p style="text-indent:-2em;margin-left:6em;">• Chronic or recurrent infection</p>
<p style="text-indent:-2em;margin-left:6em;">• Conditions that predispose to infections (eg, advanced or poorly controlled diabetes)</p>
<p style="text-indent:-2em;margin-left:6em;">• Residence/travel in areas of endemic tuberculosis or mycoses (blastomycosis, coccidioidomycosis, histoplasmosis)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Injection-site reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Adalimumab is associated with <b>injection-site reactions</b> and delayed reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23063342','lexi-content-ref-18053024','lexi-content-ref-31789277','lexi-content-ref-31734937','lexi-content-ref-30006049','lexi-content-ref-28110056','lexi-content-ref-22289732','lexi-content-ref-22261535']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23063342','lexi-content-ref-18053024','lexi-content-ref-31789277','lexi-content-ref-31734937','lexi-content-ref-30006049','lexi-content-ref-28110056','lexi-content-ref-22289732','lexi-content-ref-22261535'])">Ref</a></span>). Concurrent immunomodulators (eg, methotrexate, cyclosporine) reduce the development of anti-adalimumab antibodies and may reduce risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28260984','lexi-content-ref-26559805','lexi-content-ref-25284873']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28260984','lexi-content-ref-26559805','lexi-content-ref-25284873'])">Ref</a></span>). Most reactions do not require discontinuation and do not recur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23330811']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23330811'])">Ref</a></span>). Cross-reactivity between tumor necrosis factor-alpha inhibitors is not well-described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gulsen.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gulsen.1'])">Ref</a></span>). Anti-infliximab antibodies do not crossreact with adalimumab; although, patients who develop anti-infliximab antibodies are more prone to develop anti-adalimumab antibodies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28110056']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28110056'])">Ref</a></span>). Adalimumab has been tolerated in patients with previous infusion reactions with infliximab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21535447']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21535447'])">Ref</a></span>). In contrast, there are reports of immediate hypersensitivity reactions with adalimumab in patients who had previous infliximab-related reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28110056']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28110056'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Unknown; T-cell mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28110056']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28110056'])">Ref</a></span>) or IgE-mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25725941','lexi-content-ref-29175008','lexi-content-ref-18794465']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25725941','lexi-content-ref-29175008','lexi-content-ref-18794465'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; 12 to 24 hours following injection (but may occur immediately following injection). Injection-site reactions often occur within the first month of treatment and last up to 4 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18053024','lexi-content-ref-32357984']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18053024','lexi-content-ref-32357984'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Younger age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28260984']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28260984'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Malignancy</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Lymphoma and other malignancies (some fatal) have been reported in children and adolescents receiving tumor necrosis factor-alpha inhibitors (TNFai), including adalimumab. Half of the malignancies reported in children and adolescents were lymphomas (<b>Hodgkin lymphoma</b> and <b>non-Hodgkin lymphoma</b>), while other cases varied and included rare malignancies usually associated with immunosuppression and malignancies not typically observed in this population. Most patients were receiving concomitant immunosuppressants. <b>Hepatosplenic T-cell lymphoma</b>, a rare T-cell lymphoma, has been reported (some fatal), primarily in patients with Crohn disease or ulcerative colitis treated with adalimumab and who received concomitant azathioprine or mercaptopurine; reports occurred predominantly in adolescent and young adult males.</p>
<p style="text-indent:-2em;margin-left:2em;">Long-term observational studies and meta-analyses indicate no association between TNFai therapy and an overall increased risk of cancer (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15829572','lexi-content-ref-30289537']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15829572','lexi-content-ref-30289537'])">Ref</a></span>). One study reported a significant increase in lymphomas in patients with rheumatoid arthritis (RA) receiving TNFai compared to the general population. However, there was no significant increased risk of lymphomas in patients receiving TNFai compared to those receiving csDMARD or with dose, increasing time since initiation, or cumulative duration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18467516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18467516'])">Ref</a></span>). Another study reported no difference in the risk of solid tumors in patients with RA receiving TNFai compared to those receiving csDMARDs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24685910']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24685910'])">Ref</a></span>). Other studies reported no increased risk of malignancy recurrence in patients receiving TNFai (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25107559','lexi-content-ref-20064207']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25107559','lexi-content-ref-20064207'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: May contribute to protumor activity and suppress the anti-tumor response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29593717']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29593717'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Onset: Delayed; median 30 months (range: 1 to 84 months).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Tuberculosis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Adult and pediatric patients treated with tumor necrosis factor-alpha inhibitors (TNFai) are at risk for developing active <b>tuberculosis</b> (TB) (including <b>reactivated tuberculosis</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31731980']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31731980'])">Ref</a></span>). A meta-analysis of randomized controlled trials (RTC) of TNFai versus control and registry/longitudinal cohort studies of TNFai versus other DMARDs found a significant increase in TB risk in patients with rheumatoid arthritis (RA) treated with TNFai. In the non-RTC studies, incidence rates with adalimumab were higher than etanercept. Preventive treatment for latent TB infection reduced TB risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26472414']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26472414'])">Ref</a></span>). In the RCT studies, no difference in TB rates were found; however, this failure to detect a difference in TB rates between the two groups may be due to a short observational period (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26472414']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26472414'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: TNFai interfere with TNFa induction of the granuloma, which is a crucial defense mechanism in controlling TB (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31731980']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31731980'])">Ref</a></span>). TNFai modulates T-cell number, function, and cytokine signaling, important for the control of TB infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31731980','lexi-content-ref-9826720']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31731980','lexi-content-ref-9826720'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; median 3 to ~73 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31731980']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31731980'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Residence in an area with high TB prevalence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31731980']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31731980'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Known TB exposure or ongoing risk factors for TB exposure (eg, travel to areas with high TB prevalence, residence in correctional facilities, long-term care facilities, or homeless shelters, certain healthcare workers (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10881762']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10881762'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F130473"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (12%)<span class="lexi-table-link-container"> (<a aria-label="Skin Rash table link" class="lexi-table-link" data-table-id="lexi-content-skin-rash" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-skin-rash')">table 1</a>)</span><span class="table-link" style="display:none;">Skin Rash</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Skin Rash" frame="border" id="lexi-content-skin-rash" rules="all">
<caption style="text-align:center;">
<b>Adalimumab: Adverse Reaction: Skin Rash</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Adalimumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Adalimumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">40 mg every other week</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Rheumatoid Arthritis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">705</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">690</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Positive ANA titer (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (3% to 26%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (5% to 20%; including bleeding at injection site, erythema at injection site, injection-site pruritus, pain at injection site, swelling at injection site)<span class="lexi-table-link-container"> (<a aria-label="Injection-Site Reaction table link" class="lexi-table-link" data-table-id="lexi-content-injection-site-reaction" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-injection-site-reaction')">table 2</a>)</span><span class="table-link" style="display:none;">Injection-Site Reaction</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Injection-Site Reaction" frame="border" id="lexi-content-injection-site-reaction" rules="all">
<caption style="text-align:center;">
<b>Adalimumab: Adverse Reaction: Injection-Site Reaction</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Adalimumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Adalimumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Either 24 mg/m<sup>2</sup> up to maximum 40 mg every other week or 20 mg every other week (&lt;30 kg), 40 mg every other week (≥30 kg) dependent on phase of study</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Juvenile idiopathic arthritis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">171</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">High dose: 40 mg every other week (≥40 kg) or 20 mg every other week (&lt;40 kg); low dose: 20 mg every other week (≥40 kg) or 10 mg every other week (&lt;40 kg)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Crohn disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">192</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">40 mg every other week</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Rheumatoid Arthritis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">705</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">690</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Pooled placebo-controlled clinical trials</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Increased creatine phosphokinase in blood specimen (children and adolescents: 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Sinusitis (11%), upper respiratory tract infection (17%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction (&lt;5%), atrial fibrillation (&lt;5%), cardiac arrhythmia (&lt;5%), chest pain (&lt;5%), coronary artery disease (&lt;5%), deep vein thrombosis (&lt;5%), hypertension (5%), hypertensive encephalopathy (&lt;5%), palpitations (&lt;5%), pericardial effusion (&lt;5%), pericarditis (&lt;5%), peripheral edema (&lt;5%), syncope (&lt;5%), tachycardia (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration (&lt;5%), hypercholesterolemia (6%), hyperlipidemia (7%), ketosis (&lt;5%), menstrual disease (&lt;5%), parathyroid disease (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (7%), cholecystitis (&lt;5%), cholelithiasis (&lt;5%), esophagitis (&lt;5%), gastroenteritis (&lt;5%), gastrointestinal hemorrhage (&lt;5%), nausea (9%), vomiting (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Cystitis (&lt;5%), hematuria (5%), pelvic pain (&lt;5%), urinary tract infection (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Adenoma (&lt;5%), agranulocytosis (&lt;5%), paraproteinemia (&lt;5%), polycythemia (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic necrosis (&lt;5%), increased serum alkaline phosphatase (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (children and adolescents: 5% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes simplex infection (≤4%), herpes zoster infection (≤4%), serious infection (4% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Confusion (&lt;5%), myasthenia (&lt;5%), paresthesia (&lt;5%), subdural hematoma (&lt;5%), torso pain (&lt;5%), tremor (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (3%), arthritis (&lt;5%, including pyogenic arthritis), arthropathy (&lt;5%), back pain (6%), bone disease (&lt;5%), bone fracture (&lt;5%), limb pain (&lt;5%), muscle cramps (&lt;5%), osteonecrosis (&lt;5%), synovitis (&lt;5%), tendinopathy (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Cataract (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Nephrolithiasis (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Asthma (&lt;5%), bronchospasm (&lt;5%), dyspnea (&lt;5%), flu-like symptoms (7%), pharyngitis (≤4%), pleural effusion (&lt;5%), pneumonia (≤4%), respiratory depression (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Abnormal healing (&lt;5%), accidental injury (10%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Neuromuscular &amp; skeletal: Lupus-like syndrome (Schiff 2006)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Basal cell carcinoma of skin, cellulitis, erysipelas, malignant melanoma, skin granuloma (annulare; children and adolescents)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Appendicitis</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Uterine hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Carcinoma (including breast, gastrointestinal, lung, skin, urogenital), malignant lymphoma, neutropenia (children and adolescents)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum transaminases</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Atypical mycobacterial infection, bacterial infection, fungal infection (including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, and infection due to an organism in genus Pneumocystis), influenza (H1N1), opportunistic infection (including <i>Legionella</i> and listeriosis), parasitic infection, postoperative infection, sepsis (including catheter related sepsis), viral infection</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myositis (children and adolescents), septic arthritis</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Pyelonephritis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis, nasopharyngitis, streptococcal pharyngitis (children and adolescents), tuberculosis (including reactivated tuberculosis; disseminated, miliary, lymphatic, peritoneal, and pulmonary)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Heart failure (Mansitó López 2021), pulmonary embolism, vasculitis (systemic), worsening of heart failure</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, cutaneous lupus erythematosus (Gonzalez-Cuevas 2020), eczematous rash (Moustou 2009), erythema multiforme, fixed drug eruption, lichenoid eruption (Moustou 2009), Merkel cell carcinoma, psoriasiform eruption (Bae 2018a), psoriasis (including new onset, palmoplantar, pustular, or exacerbation), pustular rash (Moustou 2009), Stevens-Johnson syndrome (Mounach 2013), urticaria (Grace 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diverticulitis of the gastrointestinal tract, gastrointestinal perforation (appendiceal perforations), intestinal perforation, pancreatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Aplastic anemia, hepatosplenic T-cell lymphomas (children, adolescents, and young adults), leukopenia, pancytopenia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Autoimmune hepatitis (Adar 2010), cholestatic hepatitis (Latus 2013), hepatic failure, hepatitis, hepatotoxicity (idiosyncratic) (Chalasani 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (Steenholdt 2012), angioedema (Hansel 2019), hypersensitivity angiitis (Amarantee 2015), nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Sarcoidosis</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Reactivation of HBV (Loomba 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cerebrovascular accident, demyelinating disease (peripheral; including Guillain-Barré syndrome) (Kemanetzoglou 2017), demyelinating disease of the central nervous system (including multiple sclerosis) (Kemanetzoglou 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Optic neuritis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Interstitial lung disease (including pulmonary fibrosis)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (Choi 2021)</p></div>
<div class="block coi drugH1Div" id="F130486"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Known hypersensitivity to adalimumab or any component of the formulation; severe infection (eg, sepsis, tuberculosis, opportunistic infection); moderate-to-severe heart failure (NYHA class III/IV)</p></div>
<div class="block war drugH1Div" id="F130471"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Antibody formation: Formation of neutralizing anti-drug antibodies may occur with biologic tumor necrosis factor (TNF) inhibitors and may be associated with loss of efficacy (AAD-NPF [Menter 2019]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic disorders: Rare cases of pancytopenia and aplastic anemia have been reported with TNF-blockers. Patients must be advised to seek medical attention if they develop signs and symptoms suggestive of blood dyscrasias; discontinue if significant hematologic abnormalities are confirmed. Use with caution in patients with a history of significant hematologic abnormalities.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Active infection: Do not initiate therapy in patients with an active infection, including clinically important localized infection.</p>
<p style="text-indent:-2em;margin-left:4em;">• HIV: Use with caution in HIV-positive patients; TNF-α inhibitors may be appropriate in patients receiving highly active antiretroviral therapy, provided they have normal CD4 counts, no viral load, and no recent opportunistic infections (AAD-NPF [Menter 2019]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Patients with rheumatic musculoskeletal disease undergoing hip or knee replacement surgery: Hold biologic disease-modifying antirheumatic drugs (DMARDs) prior to surgery and plan surgery after the next dose is due. Surgery can occur after holding medication for 1 full dosing cycle (eg, for medications administered every 4 weeks, schedule surgery 5 weeks from last administered dose); therapy can be restarted once surgical wound shows evidence of healing (eg, no swelling, erythema, or drainage), sutures/staples are removed, and no ongoing nonsurgical site infections (typically ~14 days to reduce infection risk). Decisions to withhold therapy should be based on shared decision making; ensure the patient and their provider weigh risks of interrupting therapy and disease control versus risks of continuing therapy and surgical complications (ACR/AAHKS [Goodman 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Surgery patients: Limited experience with patients undergoing surgical procedures while on therapy; consider long half-life with planned procedures. Monitor closely for infection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Latex: The packaging (needle cover of prefilled syringe and autoinjector) may contain latex.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Immunizations: Patients should be brought up to date with all immunizations before initiating therapy; live vaccines should not be given concurrently. There are no data available concerning the effects of therapy on vaccination or secondary transmission of live vaccines in patients receiving therapy.</p></div>
<div class="block dosfc drugH1Div" id="F51937427"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">Humira 10 mg/0.1 mL, 20 mg/0.2 mL, 40 mg/0.4 mL, and 80 mg/0.8 mL formulations are citrate free. All Humira biosimilars are citrate free except for Hadlima 40 mg/0.8 mL.</p></div>
<div class="block foc drugH1Div" id="F130481"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Auto-injector Kit, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hulio: Adalimumab-fkjp 40 mg/0.8 mL (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Adalimumab-adbm 40 mg/0.8 mL (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Auto-injector Kit, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Abrilada: Adalimumab-afzb 40 mg/0.8 mL (1 ea) [contains edetate (edta) disodium dihydrate, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cyltezo: Adalimumab-adbm 40 mg/0.8 mL (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cyltezo-CD/UC/HS Starter: Adalimumab-adbm 40 mg/0.8 mL (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cyltezo-Psoriasis Starter: Adalimumab-adbm 40 mg/0.8 mL (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Idacio: Adalimumab-aacf 40 mg/0.8 mL (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Idacio for Crohns Disease/UC: Adalimumab-aacf 40 mg/0.8 mL (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Idacio for Plaque Psoriasis: Adalimumab-aacf 40 mg/0.8 mL (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Yuflyma: Adalimumab-aaty 80 mg/0.8 mL (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Yuflyma 1-Pen Kit: Adalimumab-aaty 40 mg/0.4 mL (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Yuflyma 2-Pen Kit: Adalimumab-aaty 40 mg/0.4 mL (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Yuflyma-CD/UC/HS Starter: Adalimumab-aaty 80 mg/0.8 mL (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Adalimumab-aacf 40 mg/0.8 mL (1 ea); Adalimumab-fkjp 40 mg/0.8 mL (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Pen-injector Kit, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Humira Pen: 40 mg/0.8 mL (1 ea); 40 mg/0.4 mL (1 ea); 80 mg/0.8 mL (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Humira Pen-CD/UC/HS Starter: 40 mg/0.8 mL (1 ea); 80 mg/0.8 mL (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Humira Pen-Pediatric UC Start: 80 mg/0.8 mL (1 ea) [latex free; contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Humira Pen-Ps/UV/Adol HS Start: 40 mg/0.8 mL (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Humira Pen-Psor/Uveit Starter: 80 MG/0.8ML &amp; 40MG/0.4ML (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Prefilled Syringe Kit, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hulio: Adalimumab-fkjp 40 mg/0.8 mL (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Yuflyma 2-Syringe Kit: Adalimumab-aaty 40 mg/0.4 mL (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg/0.4 mL (1 ea); 40 mg/0.8 mL (1 ea); Adalimumab-adbm 10 MG/0.2 mL (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Prefilled Syringe Kit, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Abrilada: Adalimumab-afzb 20 mg/0.4 mL (1 ea); Adalimumab-afzb 40 mg/0.8 mL (1 ea) [contains edetate (edta) disodium dihydrate, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cyltezo: 20 mg/0.4 mL (1 ea); 40 mg/0.8 mL (1 ea); Adalimumab-adbm 10 MG/0.2 mL (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hulio: Adalimumab-fkjp 20 mg/0.4 mL (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Humira: 10 mg/0.2 mL (1 ea [DSC]); 20 mg/0.4 mL (1 ea [DSC]); 40 mg/0.8 mL (1 ea); 10 mg/0.1 mL (1 ea); 20 mg/0.2 mL (1 ea); 40 mg/0.4 mL (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Humira Pediatric Crohns Start: 80 mg/0.8 mL (1 ea); 80 MG/0.8ML &amp; 40MG/0.4ML (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Idacio: Adalimumab-aacf 40 mg/0.8 mL (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Adalimumab-fkjp 20 mg/0.4 mL (1 ea); Adalimumab-fkjp 40 mg/0.8 mL (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20,000 pn unit/mL (10 mL [DSC], 50 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Auto-injector, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Amjevita: Adalimumab-atto 40 mg/0.4 mL (0.4 mL); Adalimumab-atto 80 mg/0.8 mL (0.8 mL); Adalimumab-atto 40 mg/0.8 mL (0.8 mL) [latex free; contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hadlima PushTouch: Adalimumab-bwwd 40 mg/0.4 mL (0.4 mL); Adalimumab-bwwd 40 mg/0.8 mL (0.8 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hyrimoz: Adalimumab-adaz 40 mg/0.4 mL (0.4 mL); Adalimumab-adaz 40 mg/0.8 mL (0.8 mL) [latex free; contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hyrimoz: Adalimumab-adaz 40 mg/0.4 mL (0.4 mL); Adalimumab-adaz 80 mg/0.8 mL (0.8 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hyrimoz-Crohns/UC Starter: Adalimumab-adaz 80 mg/0.8 mL (0.8 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hyrimoz-Plaque Psoriasis Start: Adalimumab-adaz 80 mg/0.8 mL and 40 mg/0.4 mL (1.6 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Adalimumab-adaz 40 mg/0.4 mL (0.4 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Pen-injector, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Yusimry: Adalimumab-aqvh 40 mg/0.8 mL (0.8 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Amjevita: Adalimumab-atto 20 mg/0.4 mL (0.4 mL); Adalimumab-atto 40 mg/0.8 mL (0.8 mL) [latex free; contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Amjevita: Adalimumab-atto 20 mg/0.2 mL (0.2 mL); Adalimumab-atto 40 mg/0.4 mL (0.4 mL) [latex free; contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Amjevita: Adalimumab-atto 10 mg/0.2 mL (0.2 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hadlima: Adalimumab-bwwd 40 mg/0.4 mL (0.4 mL); Adalimumab-bwwd 40 mg/0.8 mL (0.8 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hyrimoz: Adalimumab-adaz 40 mg/0.4 mL (0.4 mL); Adalimumab-adaz 40 mg/0.8 mL (0.8 mL) [latex free; contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hyrimoz: Adalimumab-adaz 10 mg/0.1 mL (0.1 mL); Adalimumab-adaz 20 mg/0.2 mL (0.2 mL); Adalimumab-adaz 40 mg/0.4 mL (0.4 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hyrimoz-Ped&gt;/=40kg Crohn Start: Adalimumab-adaz 80 mg/0.8 mL (0.8 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hyrimoz-Ped&lt;40kg Crohn Starter: Adalimumab-adaz 80 mg/0.8 mL (1.2 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Adalimumab-adaz 40 mg/0.4 mL (0.4 mL)</p></div>
<div class="block geq drugH1Div" id="F130468"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F130487"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Auto-injector Kit</b> (Abrilada Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/0.8 mL (per each): $3,945.90</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Auto-injector Kit</b> (Adalimumab-aacf Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/0.8 mL (per each): $1,078.80</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Auto-injector Kit</b> (Adalimumab-adbm Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/0.8 mL (per each): $789.18</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Auto-injector Kit</b> (Adalimumab-fkjp Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/0.8 mL (per each): $597.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Auto-injector Kit</b> (Cyltezo Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/0.8 mL (per each): $3,945.90</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Auto-injector Kit</b> (Cyltezo-CD/UC/HS Starter Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/0.8 mL (per each): $3,945.89</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Auto-injector Kit</b> (Cyltezo-Psoriasis Starter Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/0.8 mL (per each): $3,945.90</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Auto-injector Kit</b> (Hulio Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/0.8 mL (per each): $3,945.90</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Auto-injector Kit</b> (Idacio for Crohns Disease/UC Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/0.8 mL (per each): $7,891.79</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Auto-injector Kit</b> (Idacio for Plaque Psoriasis Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/0.8 mL (per each): $7,891.79</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Auto-injector Kit</b> (Idacio Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/0.8 mL (per each): $7,891.79</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Auto-injector Kit</b> (Yuflyma 1-Pen Kit Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/0.4 mL (per each): $3,945.90</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Auto-injector Kit</b> (Yuflyma 2-Pen Kit Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/0.4 mL (per each): $7,891.80</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Auto-injector Kit</b> (Yuflyma Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg/0.8 mL (per each): $3,945.90</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Auto-injector Kit</b> (Yuflyma-CD/UC/HS Starter Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg/0.8 mL (per each): $3,945.90</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pen-injector Kit</b> (Humira Pen Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/0.4 mL (per each): $4,153.57</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/0.8 mL (per each): $4,153.57</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg/0.8 mL (per each): $8,307.16</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pen-injector Kit</b> (Humira Pen-CD/UC/HS Starter Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/0.8 mL (per each): $4,153.59</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg/0.8 mL (per each): $8,307.18</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pen-injector Kit</b> (Humira Pen-Pediatric UC Start Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg/0.8 mL (per each): $8,307.16</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pen-injector Kit</b> (Humira Pen-Ps/UV/Adol HS Start Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/0.8 mL (per each): $4,153.58</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pen-injector Kit</b> (Humira Pen-Psor/Uveit Starter Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 MG/0.8ML &amp;40MG/0.4ML (per each): $5,538.11</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Prefilled Syringe Kit</b> (Abrilada Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/0.4 mL (per each): $3,945.90</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/0.8 mL (per each): $3,945.90</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Prefilled Syringe Kit</b> (Adalimumab-adbm Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/0.2 mL (per each): $789.18</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/0.4 mL (per each): $789.18</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/0.8 mL (per each): $789.18</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Prefilled Syringe Kit</b> (Adalimumab-fkjp Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/0.4 mL (per each): $597.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/0.8 mL (per each): $597.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Prefilled Syringe Kit</b> (Cyltezo Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/0.2 mL (per each): $3,945.90</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/0.4 mL (per each): $3,945.90</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/0.8 mL (per each): $3,945.90</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Prefilled Syringe Kit</b> (Hulio Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/0.4 mL (per each): $3,945.90</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/0.8 mL (per each): $3,945.90</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Prefilled Syringe Kit</b> (Humira Pediatric Crohns Start Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg/0.8 mL (per each): $8,307.18</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 MG/0.8ML &amp;40MG/0.4ML (per each): $6,230.38</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Prefilled Syringe Kit</b> (Humira Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10MG/0.1ML (per each): $4,153.57</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/0.2 mL (per each): $4,153.57</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/0.4 mL (per each): $4,153.57</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/0.8 mL (per each): $4,153.57</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Prefilled Syringe Kit</b> (Idacio Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/0.8 mL (per each): $7,891.79</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Prefilled Syringe Kit</b> (Yuflyma 2-Syringe Kit Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/0.4 mL (per each): $7,891.80</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Auto-injector</b> (Adalimumab-adaz Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/0.4 mL (per 0.4 mL): $789.18</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Auto-injector</b> (Amjevita Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/0.8 mL (per 0.8 mL): $1,869.11</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Auto-injector</b> (Hadlima PushTouch Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/0.4 mL (per 0.4 mL): $622.80</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/0.8 mL (per 0.8 mL): $622.80</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Auto-injector</b> (Hyrimoz Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/0.4 mL (per 0.4 mL): $780.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/0.8 mL (per 0.8 mL): $780.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg/0.8 mL (per 0.8 mL): $7,891.81</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Auto-injector</b> (Hyrimoz-Crohns/UC Starter Pack Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg/0.8 mL (per 0.8 mL): $7,891.82</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Auto-injector</b> (Hyrimoz-Plaque Psoriasis Start Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 MG/0.8ML &amp;40MG/0.4ML (per mL): $9,864.76</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Pen-injector</b> (Yusimry Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/0.8 mL (per 0.8 mL): $597.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Adalimumab-adaz Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/0.4 mL (per 0.4 mL): $789.18</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Amjevita Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/0.2 mL (per 0.2 mL): $3,945.89</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/0.4 mL (per 0.4 mL): $3,945.89</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/0.8 mL (per 0.8 mL): $3,945.89</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Hadlima Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/0.4 mL (per 0.4 mL): $622.80</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/0.8 mL (per 0.8 mL): $622.80</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Hyrimoz Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10MG/0.1 ML (per 0.1 mL): $3,945.90</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/0.2 mL (per 0.2 mL): $3,945.90</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/0.4 mL (per 0.4 mL): $780.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/0.8 mL (per 0.8 mL): $780.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Hyrimoz-Ped Crohns Starter Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg/0.8 mL (per 0.8 mL): $7,891.82</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 MG/0.8ML &amp;40MG/0.4ML (per mL): $9,864.76</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52865556"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Auto-injector Kit, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Simlandi: 40 mg/0.4 mL (1 ea, 2 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Yuflyma: Adalimumab-aaty 40 mg/0.4 mL (1 ea, 2 ea, 4 ea, 6 ea); Adalimumab-aaty 80 mg/0.8 mL (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Pen-injector Kit, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hulio: 40 mg/0.8 mL (2 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Prefilled Syringe Kit, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hulio: 20 mg/0.4 mL (2 ea); 40 mg/0.8 mL (2 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Simlandi: 40 mg/0.4 mL (1 ea, 2 ea); 80 mg/0.8 mL (1 ea, 2 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Yuflyma: Adalimumab-aaty 40 mg/0.4 mL (1 ea); Adalimumab-aaty 80 mg/0.8 mL (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Humira: 40 mg/0.8 mL (0.8 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Auto-injector, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Abrilada: 40 mg/0.8 mL (0.8 mL) [contains edetate (edta) disodium dihydrate, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Amgevita SureClick: 40 mg/0.8 mL (0.8 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hadlima PushTouch: 40 mg/0.8 mL (0.8 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hyrimoz: 40 mg/0.8 mL (0.8 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Idacio: 40 mg/0.8 mL (0.8 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Pen-injector, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Humira: 40 mg/0.4 mL ([DSC]) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Abrilada: 20 mg/0.4 mL (0.4 mL); 40 mg/0.8 mL (0.8 mL) [contains edetate (edta) disodium dihydrate, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Amgevita: 20 mg/0.4 mL (0.4 mL); 40 mg/0.8 mL (0.8 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hadlima: 40 mg/0.8 mL (0.8 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Humira: 20 mg/0.2 mL (0.2 mL); 40 mg/0.4 mL ([DSC]) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hyrimoz: 20 mg/0.4 mL (0.4 mL); 40 mg/0.8 mL (0.8 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Idacio: 40 mg/0.8 mL (0.8 mL) [contains polysorbate 80]</p></div>
<div class="block admp drugH1Div" id="F52612183"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">SubQ: Administer subcutaneously into thigh or lower abdomen (avoid areas within 2 inches of navel); rotate injection sites. If single dose requires multiple injections, administer each injection at a separate site at least 1 inch apart. Do not administer into skin that is red, tender, bruised, or hard. May leave at room temperature for ~15 to 30 minutes prior to use; do not remove cap or cover while allowing product to reach room temperature. Do not use if solution is discolored or contains particulate matter.</p>
<p style="text-indent:-2em;margin-left:2em;">Single-use vial: Intended for institutional use only; does not contain a preservative; discard unused portion.</p>
<p style="text-indent:-2em;margin-left:2em;">Prefilled pens/syringe: Citrate-free formulations are available and may be associated with less pain on injection. Needle cap of the prefilled syringe or needle cover may contain latex. Pinch area of skin prepped for injection and continue to hold until injection complete. Hold pen firmly against pinched skin and press button. A loud click is heard when injection has begun. Continue to hold pen against skin until injection complete (may take 10 seconds). When injection is complete, the yellow indicator will fully appear in the window view and stop moving. See product labeling for administration details.</p></div>
<div class="block adm drugH1Div" id="F130483"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>SUBQ:</b> For SUBQ injection at separate sites in the thigh or lower abdomen (avoiding areas within 2 inches of navel); rotate injection sites. May leave at room temperature for ~15 to 30 minutes prior to use; do not remove cap or cover while allowing product to reach room temperature. Do not use if solution is discolored or contains particulate matter. Do not administer to skin which is red, tender, bruised, hard, or that has scars, stretch marks, or psoriasis plaques. Needle cap of the prefilled syringe or needle cover for the adalimumab pen may contain latex. Prefilled pens and syringes are available for use by patients and the full amount of the syringe should be injected (self-administration); the vial is intended for institutional use only. Vials do not contain a preservative; discard unused portion. Citrate-free formulations may be associated with less pain on injection.</p></div>
<div class="block sts drugH1Div" id="F130495"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 2°C to 8°C (36°F to 46°F) in original container to protect from light; do not freeze. Do not use if frozen even if it has been thawed. Do not store in extreme heat or cold. If needed, may be stored at room temperature; allowable temperature range and duration of storage vary by product; refer to manufacturer’s labeling for detailed recommendations.</p></div>
<div class="block meg drugH1Div" id="F7874545"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Abrilada (adalimumab-afzb): <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F761118s007lbl.pdf%23page%3D47&amp;token=%2F%2FlYGzkjbdA6qugV1v1mzDT1YPPrP9DI26hfA5jgkE4dF608pofddFbTWmFLYWYyARSo0RzKP3804jN6KCOBEZRUJpa4c1pkLhOFw2q2aFFZ51ewr754E8lgJ3ZStVdC&amp;TOPIC_ID=13077" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761118s007lbl.pdf#page=47</a></p>
<p style="text-indent:-2em;margin-left:4em;">Amjevita (adalimumab-atto): <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F761024s015lbl.pdf%23page%3D50&amp;token=%2FiRfqFk0vUSXqmJBEkb%2FWF5MA%2Fpo%2FowG9GtPXLHhO%2FxJjbICjyoU%2ByldY7ChkiGMa8oU1LwFag0Zo9CznM4fdcc8r3IxrNhVI4gmQMVGuXyPjCYAbQTjNnUD%2F9eRii3b&amp;TOPIC_ID=13077" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761024s015lbl.pdf#page=50</a></p>
<p style="text-indent:-2em;margin-left:4em;">Cyltezo (adalimumab-adbm): <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F761058s018lbl.pdf%23page%3D38&amp;token=v3%2F4hHvGqEbS%2FqrGiLEVw15MA%2Fpo%2FowG9GtPXLHhO%2Fwh7cbohVJ5aJRqykD%2FoIs9PeC%2Bfh8Urg0tzPDcnNwhfR0l0iIgXhIaZ2hh75AiMUoTjjKaQT2SRlSfwWz5KP4V&amp;TOPIC_ID=13077" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761058s018lbl.pdf#page=38</a></p>
<p style="text-indent:-2em;margin-left:4em;">Hadlima (adalimumab-bwwd): <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F761059s008lbl.pdf%23page%3D46&amp;token=n2AU3D6PkeTLMiFxY%2BFLC%2BmKffYdUiw5%2F979SWrjThMF43JhOXwGT34LTrtQ%2FYUeZF1QiNjnKGOiQXsGtnKo15O2M7PB8OCsn40ZDn9XSDtnP8n6CW4sQMMEtvOVsOfr&amp;TOPIC_ID=13077" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761059s008lbl.pdf#page=46</a></p>
<p style="text-indent:-2em;margin-left:4em;">Hulio (adalimumab-fkjp): <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F761154s005lbl.pdf%23page%3D57&amp;token=dxXm07mjhXd9FYaT8FkcPk45R64%2FzyxtrcSHg0ukT%2BK%2BFhpetrC3OXsg0syHTwZ6eyUJ3DgWU8Z2iOWTggiVF5DMjphiEoaGCkmi0Yk5XjU%2FRO6D%2BhaaK%2Fy424MSrGwZ&amp;TOPIC_ID=13077" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761154s005lbl.pdf#page=57</a></p>
<p style="text-indent:-2em;margin-left:4em;">Humira: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F125057s423lbl.pdf%23page%3D57&amp;token=cD5BqvxrtHdqqaZIe91LBGlauuwpjRMSh%2BXN8bb%2FeEd2RzfYuUtrKSGX9qipCE%2FrD5LAcuHojmn3VT0u87s5gWbEUqYU45Gqro3rLeAm08jZ5twmD6r%2Bb1nkBm4VShzv&amp;TOPIC_ID=13077" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125057s423lbl.pdf#page=57</a></p>
<p style="text-indent:-2em;margin-left:4em;">Hyrimoz (adalimumab-adaz): <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F761071s016lbl.pdf%23page%3D60&amp;token=QpM1PPzbfrFF3GVIQipk3RVhaTrcTAvtY%2FYdJMVfVVUvU9SzbzgQPEsVtPfLg%2FTSPKRUg5GE1pUGWfCfKE%2BWta5s%2BQR8DPbj3DHX6b9OCS0II9%2BHUojzp7IC7NY1JMK1&amp;TOPIC_ID=13077" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761071s016lbl.pdf#page=60</a></p>
<p style="text-indent:-2em;margin-left:4em;">Idacio (adalimumab-aacf): <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F761255s003lbl.pdf%23page%3D49&amp;token=rtMHp4m1etJpNGCFxi0NrbV5uEbOiQEVdbj9SeqIY7GJ7dUJEiRxd9QWtXAiBdgYCz1Elz%2FRnyLcwyDI%2BoiMqDJm19lHajuOEtusNGLfDRgswcVD1DCGpKGaoo1LjHj0&amp;TOPIC_ID=13077" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761255s003lbl.pdf#page=49</a></p>
<p style="text-indent:-2em;margin-left:4em;">Yuflyma (adalimumab-aaty): <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F761219s000lbl.pdf%23page%3D39&amp;token=5ayEi%2FISCKsxRSqpfMyMcJCy7wj%2Fu1rJwzzfM7AfIAG%2BzVdGPbn%2Bn5X%2B%2FQJ3HmWlMF1p7rHQKAPVBuYs57gs%2BpLkQJYRFT4%2BVm1EABMMR6Fp%2F2SacfPSWe8q6VIWps3K&amp;TOPIC_ID=13077" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761219s000lbl.pdf#page=39</a></p>
<p style="text-indent:-2em;margin-left:4em;">Yusimry (adalimumab-aqvh): <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F761216s004lbl.pdf%23page%3D56&amp;token=wQ9aLTIaWwxzKnxMeFQi%2BEq6%2FQ0to%2FtxWBW26yKHR3gdF608pofddFbTWmFLYWYyohETRlJ3PIueMtm7I%2BxaOZ0ClzbC0g5x6v0vzBYlFWC1Od5pVvkzqXdp5lkab1ze&amp;TOPIC_ID=13077" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761216s004lbl.pdf#page=56</a></p></div>
<div class="block usep drugH1Div" id="F53565209"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) alone or in combination with methotrexate (Humira: FDA approved in ages 2 to 17 years weighing ≥10 kg); treatment and maintenance of remission in patients with moderately to severely active ulcerative colitis (Humira: FDA approved in ages ≥5 years and adults); treatment and maintenance of remission in patients with moderately to severely active Crohn disease (Humira: FDA approved in ages ≥6 years and adults); treatment of noninfectious intermediate, posterior, and panuveitis (Humira: FDA approved in ages ≥2 years weighing ≥10 kg and adults); treatment of moderate to severe hidradenitis suppurativa (Humira: FDA approved in ages ≥12 years weighing ≥30 kg and adults); treatment of moderately to severely active rheumatoid arthritis (RA) alone or in combination with methotrexate or other nonbiologic, disease-modifying antirheumatic drugs (DMARDs) (Humira: FDA approved in adults); treatment of active psoriatic arthritis alone or in combination with nonbiologic DMARDs (Humira: FDA approved in adults); treatment of active ankylosing spondylitis (Humira: FDA approved in adults); treatment of moderate to severe chronic plaque psoriasis when systemic therapy is required and other agents are less appropriate (Humira: FDA approved in adults).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> In the United States, Amjevita (adalimumab-atto) has been approved as a biosimilar to Humira (adalimumab). In Canada, Abrilada, Amgevita, Hadlima, Hulio, Hyrimoz, Idacio, Simlandi, and Yuflyma are also approved as biosimilars to Humira; refer to Canadian product monograph(s) for biosimilar-specific indication details. Approved ages and uses may vary (consult product labeling).</p></div>
<div class="block mst drugH1Div" id="F130521"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Adalimumab may be confused with sarilumab.</p>
<p style="text-indent:-2em;margin-left:4em;">Humira may be confused with Humulin, Humalog</p>
<p style="text-indent:-2em;margin-left:4em;">Humira Pen may be confused with HumaPen Memoir (used with HumaLOG)</p>
<p style="text-indent:-2em;margin-left:4em;">Yuflyma may be confused with Yusimry</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298685"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F130475"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abatacept: Anti-TNF Agents may enhance the immunosuppressive effect of Abatacept. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anakinra: Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anifrolumab: Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) may enhance the immunosuppressive effect of Anifrolumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Belimumab: May enhance the immunosuppressive effect of Biologic Disease-Modifying Antirheumatic Drugs (DMARDs). Management: Consider alternatives to the use of belimumab with other biologic therapies. Monitor closely for increased toxicities related to additive immunosuppression (ie, infection, malignancy) if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Biologic Disease-Modifying Antirheumatic Drugs (DMARDs): May enhance the immunosuppressive effect of other Biologic Disease-Modifying Antirheumatic Drugs (DMARDs).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Canakinumab: Anti-TNF Agents may enhance the adverse/toxic effect of Canakinumab. Specifically, the risk for serious infections and/or neutropenia may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Certolizumab Pegol: Anti-TNF Agents may enhance the immunosuppressive effect of Certolizumab Pegol. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing therapeutic immunosuppressants several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Adalimumab may decrease the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP Substrates (Narrow Therapeutic Index/Sensitive with Inducers): Adalimumab may decrease the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inducers). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Denosumab.  Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate 2 to 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Pimecrolimus. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rilonacept: Anti-TNF Agents may enhance the adverse/toxic effect of Rilonacept. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: Adalimumab may decrease the serum concentration of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiopurine Analogs: Anti-TNF Agents may enhance the adverse/toxic effect of Thiopurine Analogs. Specifically, the risk for T-cell non-Hodgkin's lymphoma (including hepatosplenic T-cell lymphoma) may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tofacitinib.  Management: Coadministration of tofacitinib with potent immunosuppressants is not recommended. Use with non-biologic disease-modifying antirheumatic drugs (DMARDs) was permitted in psoriatic arthritis clinical trials.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 2 to 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vedolizumab: Anti-TNF Agents may enhance the adverse/toxic effect of Vedolizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53704706"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">The American Academy of Dermatology considers tumor necrosis factor (TNF) blocking agents for the treatment of psoriasis to be compatible for use in patients planning to father a child (AAD-NPF [Menter 2019]). Patients with psoriasis planning to become pregnant may continue treatment with adalimumab. Patients with well-controlled psoriasis who wish to avoid fetal exposure can consider discontinuing adalimumab 10 weeks prior to attempting to become pregnant (Rademaker 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Biologics, such as adalimumab, may be continued in patients with inflammatory bowel disease (eg, Crohn disease, ulcerative colitis) planning to become pregnant (Mahadevan 2019). Treatment algorithms are available for use of biologics in patients with Crohn disease who are planning to become pregnant (Weizman 2019).</p></div>
<div class="block pri drugH1Div" id="F130488"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adalimumab crosses the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">Adalimumab is a humanized monoclonal antibody (IgG<sub>1</sub>). Placental transfer of human IgG is dependent upon the IgG subclass, maternal serum concentrations, birth weight, and gestational age, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis (Palmeira 2012; Pentsuk 2009).</p>
<p style="text-indent:0em;margin-top:2em;">Following administration to pregnant patients with inflammatory bowel disease (eg, Crohn disease, ulcerative colitis), cord blood and newborn serum concentrations of adalimumab are greater than maternal serum at delivery (Julsgaard 2016; Mahadevan 2013). The mean time to adalimumab clearance was 4 months (range: 2.9 to 5 months) in a study in 36 infants exposed in utero. The estimated mean half-life of adalimumab in these infants was 26 days (Julsgaard 2016). One case report notes adalimumab was detectable in the infant serum for 19 months following in utero exposure (Labetoulle 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Based on available data, an increased risk of adverse maternal or fetal effects has not been observed following adalimumab exposure during pregnancy (Nielsen 2020). Adalimumab information from a pregnancy registry collected between 2004 and 2016 is available. Included were pregnant women with rheumatoid arthritis (RA) or Crohn disease (CD) treated with adalimumab at least during the first trimester (n=257), pregnant women with RA or CD not treated with adalimumab (disease untreated control, n=120), and pregnant women without RA or CD (healthy unexposed control, n=225); 42 cases lost to follow-up. The incidence of major birth defects was not significantly different between the study groups and no pattern of specific defects was observed. An increased risk of growth restriction or serious opportunistic infections was not associated with maternal adalimumab therapy when compared to the disease untreated controls. An increased risk of preterm delivery was observed in pregnant patients with RA or CD, regardless of adalimumab exposure (Chambers 2019). Information related to this class of medications is emerging, but based on available data, tumor necrosis factor alpha (TNFα) blocking agents are considered to have low to moderate risk when used in pregnancy (ACOG 776 2019).</p>
<p style="text-indent:0em;margin-top:2em;">The risk of immunosuppression may be increased following third trimester maternal use of TNFα blocking agents; the fetus, neonate/infant should be considered immunosuppressed for 1 to 3 months following in utero exposure (AAD-NPF [Menter 2019]). Vaccination with live vaccines (eg, rotavirus vaccine) should be avoided for the first 6 months of life if exposure to a biologic agent occurs during the third trimester of pregnancy (eg, &gt;27 weeks' gestation) (Mahadevan 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Maternal adalimumab serum concentrations remain stable as pregnancy progresses (Flanagan 2020; Seow 2017).</p>
<p style="text-indent:0em;margin-top:2em;">Inflammatory bowel disease is associated with adverse pregnancy outcomes including an increased risk of miscarriage, premature delivery, delivery of a low birth weight infant, and poor maternal weight gain. Management of maternal disease should be optimized prior to pregnancy. Treatment decreases disease flares, disease activity, and the incidence of adverse pregnancy outcomes (Mahadevan 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Use of immune modulating therapies in pregnancy should be individualized to optimize maternal disease and pregnancy outcomes (ACOG 776 2019). The American Academy of Dermatology considers TNFα blocking agents for the treatment of psoriasis to be compatible with pregnancy (AAD-NPF [Menter 2019]). When treatment for inflammatory bowel disease is needed in pregnant women, appropriate biologic therapy can be continued without interruption. Serum levels should be evaluated prior to conception and optimized to avoid subtherapeutic concentrations or high levels which may increase placental transfer. Dosing can be adjusted so delivery occurs at the lowest serum concentration. For adalimumab, the final injection can be given 2 to 3 weeks prior to the estimated date of delivery (1 to 2 weeks if weekly dosing), then continued 48 hours postpartum (Mahadevan 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to adalimumab is ongoing. Women exposed to adalimumab during pregnancy for the treatment of an autoimmune disease (eg, inflammatory bowel disease) may contact the OTIS Autoimmune Diseases Study at 877-311-8972.</p></div>
<div class="block mopp drugH1Div" id="F53565210"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor improvement of symptoms and physical function assessments. Latent TB screening prior to initiating and during therapy; signs/symptoms of infection (prior to, during, and following therapy); CBC with differential; signs/symptoms/worsening of heart failure; LFTs at baseline; HBV screening prior to initiating (all patients), HBV carriers (during and for several months following therapy); signs and symptoms of hypersensitivity reaction; symptoms of lupus-like syndrome; signs/symptoms of malignancy (eg, splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss), including periodic skin examination.</p></div>
<div class="block rerp drugH1Div" id="F54941265"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Crohn disease</i> (ECCO/ESPGHAN [van Rheenen 2020]): Early proactive therapeutic monitoring is recommended to optimize dose and prevent underdosing in pediatric Crohn disease patients.</p>
<p style="text-indent:-2em;margin-left:4em;">Timing of serum sample: Prior to third injection (4 weeks after first dose).</p>
<p style="text-indent:-2em;margin-left:4em;">Therapeutic concentrations: 7.5 to 10 mcg/mL.</p></div>
<div class="block pha drugH1Div" id="F130470"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Adalimumab is a recombinant monoclonal antibody that binds to human tumor necrosis factor alpha (TNF-alpha), thereby interfering with binding to TNFα receptor sites and subsequent cytokine-driven inflammatory processes. Elevated TNF levels in the synovial fluid are involved in the pathologic pain and joint destruction in immune-mediated arthritis. Adalimumab decreases signs and symptoms of psoriatic arthritis, rheumatoid arthritis, and ankylosing spondylitis. It inhibits progression of structural damage of rheumatoid and psoriatic arthritis. Reduces signs and symptoms and maintains clinical remission in Crohn disease and ulcerative colitis; reduces epidermal thickness and inflammatory cell infiltration in plaque psoriasis.</p></div>
<div class="block phk drugH1Div" id="F130485"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Response best determined after 3 to 4 months (AAD-NPF [Menter 2019]).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 4.7 to 6 L; Synovial fluid concentrations: 31% to 96% of serum</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Absolute: 64%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Terminal: ~2 weeks (range: 10 to 20 days)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: SUBQ: 131 ± 56 hours</p></div>
<div class="block phksp drugH1Div" id="F51219891"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Older adult: In patients with rheumatoid arthritis (RA), there was a trend toward lower clearance with increasing age in patients 40 to &gt;75 years of age.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F130489"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Amgevita | Humira | Hyrimoz</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Amgevita | Humira | Humira ac</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Amgevita | Hukyndra | Hulio | Humira | Hyrimoz | Idacio | Imraldi | Yuflyma</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Amgevita | Hadlima | Humira | Hyrimoz | Idacio | Yuflyma</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Amgevita | Amsparity | Hukyndra | Hulio | Humira | Hyrimoz | Idacio | Imraldi | Yuflyma</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Amgevita | Hukyndra | Hulio | Humira | Hyrimoz | Yuflyma</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Amgevita | Humira | Hyrimoz | Idacio | Xilbrilada</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Abrilada | Amgevita | Hulio | Humira | Hyrimoz | Idacio | Imraldi</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Amgevita | Humira | Humira ac | Hyrimoz | Idacio</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Humira | Sulinno</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Abrilada | Amgevita | Humira | Humira ac | Hyrimoz | Idacio</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Amgevita | Hukyndra | Hulio | Humira | Hyrimoz | Idacio | Imraldi | Yuflyma</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Amgevita | Cyltezo | Hukyndra | Hulio | Humira | Hyrimoz | Idacio | Imraldi | Kromeya | Libmyris | Yuflyma</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Humira</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Humira | Humira ac</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Amgevita | Humira ac | Hyrimoz</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Amgevita | Hukyndra | Hulio | Humira | Hyrimoz | Idacio | Imraldi</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Amgevita | Humira | Hyrimoz</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Amgevita | Hulio | Humira | Hyrimoz | Idacio | Imraldi | Yuflyma</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Amgevita | Hukyndra | Hulio | Humira | Hyrimoz | Idacio | Imraldi | Yuflyma</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Amgevita | Amsparity | Hukyndra | Hulio | Humira | Hyrimoz | Idacio | Imraldi | Yuflyma</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Amgevita | Hulio | Humira | Hyrimoz | Idacio | Imraldi | Yuflyma</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Amgevita | Hefiya | Hulio | Humira | Hyrimoz | Idacio | Imraldi | Yuflyma</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Amgevita | Humira | Hyrimoz</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Amgevita | Hulio | Humira | Hyrimoz | Imraldi</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Amgevita | Hulio | Humira | Idacio | Yuflyma</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Humira</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Amgevita | Cyltezo | Halimatoz | Hefiya | Hulio | Humira | Hyrimoz | Idacio | Imraldi | Yuflyma</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Adalipca | Adalirel | Adaly | Adfrar | Adlumab | Amab | Cadalimab | Envira | Exemptia | Mabura | Plamumab</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Amgevita | Humira | Hyrimoz | Idacio | Imraldi | Yuflyma</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Amgevita | Humira | Hyrimoz</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Humira</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Adalirel | Pamera</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Adalloce | Humira</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Humira | Hyrimoz</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Amgevita | Cinnora | Humira | Hyrimoz</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Amgevita | Hukyndra | Hulio | Humira | Hyrimoz | Idacio | Imraldi | Yuflyma</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Amgevita | Hulio | Humira | Hyrimoz | Imraldi | Yuflyma</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Hukyndra | Hulio | Humira | Hyrimoz | Idacio | Imraldi | Yuflyma</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Humira</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Humira | Humira ac | Hyrimoz</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Amgevita | Idacio</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Amgevita | Hukyndra | Hulio | Humira | Hyrimoz | Idacio | Imraldi | Yuflyma</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Humira | Hyrimoz | Imraldi</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Amgevita</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Amgevita | Humira</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Humira</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Amgevita | Hulio | Humira | Hyrimoz | Imraldi</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Humira</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Amgevita | Hulio | Humira | Hyrimoz | Idacio | Imraldi</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Amgevita | Humira | Humira ac</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Amgevita | Amgevita Sureclick | Hadlima | Hulio | Humira | Hyrimoz | Hyrimoz Sensoready</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Amgevita | Hukyndra | Hulio | Humira | Hyrimoz | Idacio | Imraldi</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Dalibra | Humira</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Abrilada | Amgevita | Hadlima</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Amgevita | Hukyndra | Hulio | Humira | Hyrimoz | Idacio | Imraldi</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Amgevita | Humira</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Amgevita | Hukyndra | Hulio | Humira | Hyrimoz | Idacio | Imraldi</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Amgevita | Hukyndra | Hulio | Humira | Hyrimoz | Idacio | Yuflyma</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Abrilada | Humira</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Humira</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Amgevita | Humira</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Amgevita | Idacio</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Hadlima | Humira | Hyrimoz</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Humira | Humira ac | Hyrimoz</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Amgevita | Hulio | Humira | Hyrimoz</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-A-Rahim.1">
<a name="A-Rahim.1"></a>A-Rahim YI, Farrell RJ. Overview of dosing and monitoring of biologic agents and small molecules for treating ulcerative colitis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed May 4, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Abrilada.2">
<a name="Abrilada.2"></a>Abrilada (adalimumab-afzb) [prescribing information]. New York, NY: Pfizer Inc; October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Abrilada.1">
<a name="Abrilada.1"></a>Abrilada (adalimumab) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; April 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pfizer.1">
<a name="Pfizer.1"></a>Adalimumab injection [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; January 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19593165">
<a name="19593165"></a>Adar T, Mizrahi M, Pappo O, Scheiman-Elazary A, Shibolet O. Adalimumab-induced autoimmune hepatitis. <i>J Clin Gastroenterol</i>. 2010;44(1):e20-e22. doi:10.1097/MCG.0b013e3181a745e7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/19593165/pubmed" id="19593165" target="_blank">19593165</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26472414">
<a name="26472414"></a>Ai JW, Zhang S, Ruan QL, et al. The risk of tuberculosis in patients with rheumatoid arthritis treated with tumor necrosis factor-α antagonist: a metaanalysis of both randomized controlled trials and registry/cohort studies. <i>J Rheumatol</i>. 2015;42(12):2229-2237. doi:10.3899/jrheum.150057<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/26472414/pubmed" id="26472414" target="_blank">26472414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26312693">
<a name="26312693"></a>Amarante CF, Acedo LM, Rabay FM, Campos Bdo E, Lira ML, Mandelbaum SH. Drug-induced lupus with leukocytoclastic vasculitis: a rare expression associated with adalimumab. <i>An Bras Dermatol</i>. 2015;90(3 suppl 1):121-124. doi:10.1590/abd1806-4841.20153834<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/26312693/pubmed" id="26312693" target="_blank">26312693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30913201">
<a name="30913201"></a>American College of Obstetricians and Gynecologists (ACOG). Committee opinion no. 776: immune modulating therapies in pregnancy and lactation. <i>Obstet Gynecol</i>. 2019;133(4):e287-e295.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/30913201/pubmed" id="30913201" target="_blank">30913201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Amgevita.1">
<a name="Amgevita.1"></a>Amgevita (adalimumab) [product monograph]. Mississauga, Ontario, Canada: Amgen Canada Inc; July 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Amgen.1">
<a name="Amgen.1"></a>Amjevita (adalimumab) [prescribing information]. Thousand Oaks, CA: Amgen Inc; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20038753">
<a name="20038753"></a>Angel K, Provan SA, Gulseth HL, Mowinckel P, Kvien TK, Atar D. Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. <i>Hypertension</i>. 2010;55(2):333-338. doi:10.1161/HYPERTENSIONAHA.109.143982<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/20038753/pubmed" id="20038753" target="_blank">20038753</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24458537">
<a name="24458537"></a>Arts EE, Fransen J, den Broeder AA, Popa CD, van Riel PL. The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients. <i>Ann Rheum Dis</i>. 2015;74(6):998-1003. doi:10.1136/annrheumdis-2013-204531<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/24458537/pubmed" id="24458537" target="_blank">24458537</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18467516">
<a name="18467516"></a>Askling J, Baecklund E, Granath F, et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. <i>Ann Rheum Dis</i>. 2009;68(5):648-653. doi:10.1136/ard.2007.085852<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/18467516/pubmed" id="18467516" target="_blank">18467516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15829572">
<a name="15829572"></a>Askling J, Fored CM, Brandt L, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. <i>Ann Rheum Dis</i>. 2005;64(10):1421-1426. doi:10.1136/ard.2004.033993<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/15829572/pubmed" id="15829572" target="_blank">15829572</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30637218">
<a name="30637218"></a>Averbukh LD, Wu GY. Role of biologics in the development of autoimmune hepatitis: a review. <i>J Clin Transl Hepatol</i>. 2018;6(4):402-409. doi:10.14218/JCTH.2018.00039<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/30637218/pubmed" id="30637218" target="_blank">30637218</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29859201">
<a name="29859201"></a>Bae JM, Kwon HS, Kim GM, Park KS, Kim KJ. Paradoxical psoriasis following anti-TNF therapy in ankylosing spondylitis: a population-based cohort study. <i>J Allergy Clin Immunol</i>. 2018;142(3):1001-1003.e2. doi:10.1016/j.jaci.2018.05.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/29859201/pubmed" id="29859201" target="_blank">29859201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29869804">
<a name="29869804"></a>Bae JM, Lee HH, Lee BI, et al. Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study. <i>Aliment Pharmacol Ther</i>. 2018;48(2):196-205. doi:10.1111/apt.14822<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/29869804/pubmed" id="29869804" target="_blank">29869804</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34557936">
<a name="34557936"></a>Barešić M, Reihl Crnogaj M, Zadro I, Anić B. Demyelinating disease (multiple sclerosis) in a patient with psoriatic arthritis treated with adalimumab: a case-based review. <i>Rheumatol Int</i>. 2021;41(12):2233-2239. doi:10.1007/s00296-021-04995-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/34557936/pubmed" id="34557936" target="_blank">34557936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34140301">
<a name="34140301"></a>Baughman RP, Valeyre D, Korsten P, et al. ERS clinical practice guidelines on treatment of sarcoidosis. <i>Eur Respir J.</i> 2021;58(6):2004079. doi:10.1183/13993003.04079-2020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/34140301/pubmed" id="34140301" target="_blank">34140301</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21351201">
<a name="21351201"></a>Baumgart DC, Grittner U, Steingräber A, Azzaro M, Philipp S. Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: experience from a consecutive cohort of inflammatory bowel disease patients. <i>Inflamm Bowel Dis</i>. 2011;17(12):2512-2520. doi:10.1002/ibd.21643<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/21351201/pubmed" id="21351201" target="_blank">21351201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25725941">
<a name="25725941"></a>Bavbek S, Ataman Ş, Akıncı A, Castells M. Rapid subcutaneous desensitization for the management of local and systemic hypersensitivity reactions to etanercept and adalimumab in 12 patients. <i>J Allergy Clin Immunol Pract</i>. 2015;3(4):629-632. doi:10.1016/j.jaip.2015.01.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/25725941/pubmed" id="25725941" target="_blank">25725941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23063342">
<a name="23063342"></a>Bavbek S, Ataman Ş, Bankova L, Castells M. Injection site reaction to adalimumab: positive skin test and successful rapid desensitisation. <i>Allergol Immunopathol (Madr)</i>. 2013;41(3):204-206. doi:10.1016/j.aller.2012.04.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/23063342/pubmed" id="23063342" target="_blank">23063342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20005982">
<a name="20005982"></a>Ben-Horin S, Yavzori M, Katz L, et al. Adalimumab level in breast milk of a nursing mother. <i>Clin Gastroenterol Hepatol</i>. 2010;8(5):475-476.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/20005982/pubmed" id="20005982" target="_blank">20005982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18053024">
<a name="18053024"></a>Benucci M, Manfredi M, Demoly P, Campi P. Injection site reactions to TNF-alpha blocking agents with positive skin tests. <i>Allergy</i>. 2008;63(1):138-139. doi:10.1111/j.1398-9995.2007.01536.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/18053024/pubmed" id="18053024" target="_blank">18053024</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet</i>. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25131534">
<a name="25131534"></a>Björnsson ES, Gunnarsson BI, Gröndal G, et al. Risk of drug-induced liver injury from tumor necrosis factor antagonists. <i>Clin Gastroenterol Hepatol</i>. 2015;13(3):602-608. doi:10.1016/j.cgh.2014.07.062<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/25131534/pubmed" id="25131534" target="_blank">25131534</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34487751">
<a name="34487751"></a>Björnsson HK, Gudbjornsson B, Björnsson ES. Infliximab-induced liver injury: clinical phenotypes, autoimmunity and the role of corticosteroid treatment. <i>J Hepatol</i>. 2022;76(1):86-92. doi:10.1016/j.jhep.2021.08.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/34487751/pubmed" id="34487751" target="_blank">34487751</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33151572">
<a name="33151572"></a>Boggs JME, Ramsay B, Lynch M. Paradoxical psoriasis caused by tumour necrosis factor inhibitor therapy. <i>Clin Exp Dermatol</i>. 2021;46(3):580-582. doi:10.1111/ced.14500<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/33151572/pubmed" id="33151572" target="_blank">33151572</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16705109">
<a name="16705109"></a>Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. <i>JAMA</i>. 2006;295(19):2275-2285. doi:10.1001/jama.295.19.2275<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/16705109/pubmed" id="16705109" target="_blank">16705109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26223543">
<a name="26223543"></a>Burgos-Vargas R, Tse SM, Horneff G, et al. A randomized, double-blind, placebo-controlled multicenter study of adalimumab in pediatric patients with enthesitis-related arthritis. <i>Arthritis Care Res (Hoboken)</i>. 2015;67(11):1503-1512.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/26223543/pubmed" id="26223543" target="_blank">26223543</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22562972">
<a name="22562972"></a>Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. <i>Ann Rheum Dis</i>. 2013;72(4):517-524. doi:10.1136/annrheumdis-2011-201244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/22562972/pubmed" id="22562972" target="_blank">22562972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31789277">
<a name="31789277"></a>Canu D, Seneschal J, Milpied B, Taieb A, Darrigade AS. TNFα inhibitor-induced urticaria: a class effect. <i>Eur J Dermatol</i>. 2019;29(5):543-544. doi:10.1684/ejd.2019.3625<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/31789277/pubmed" id="31789277" target="_blank">31789277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10881762">
<a name="10881762"></a>Centers for Disease Control and Prevention (CDC). Targeted tuberculin testing and treatment of latent tuberculosis infection. <i>MMWR Recomm Rep</i>. 2000;49(RR-6):1-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/10881762/pubmed" id="10881762" target="_blank">10881762</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control and Prevention (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24935270">
<a name="24935270"></a>Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/24935270/pubmed" id="24935270" target="_blank">24935270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33929376">
<a name="33929376"></a>Chalasani NP, Maddur H, Russo MW, Wong RJ, Reddy KR; Practice Parameters Committee of the American College of Gastroenterology. ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2021;116(5):878-898. doi:10.14309/ajg.0000000000001259<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/33929376/pubmed" id="33929376" target="_blank">33929376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31626646">
<a name="31626646"></a>Chambers CD, Johnson DL, Xu R, et al; OTIS Collaborative Research Group. Birth outcomes in women who have taken adalimumab in pregnancy: a prospective cohort study.<i> PLoS One.</i> 2019;14(10):e0223603. doi:10.1371/journal.pone.0223603<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/31626646/pubmed" id="31626646" target="_blank">31626646</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34496051">
<a name="34496051"></a>Chen HK, Shao SC, Weng MY, et al. Risk of heart failure in rheumatoid arthritis patients treated with tumor necrosis factor-α inhibitors. <i>Clin Pharmacol Ther</i>. 2021;110(6):1595-1603. doi:10.1002/cpt.2415<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/34496051/pubmed" id="34496051" target="_blank">34496051</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33747126">
<a name="33747126"></a>Choi SJ, Ahn SM, Oh JS, et al. Anti-tumor necrosis factor-induced lupus in patients with inflammatory bowel disease: a hospital-based cohort study from Korea. <i>Therap Adv Gastroenterol</i>. 2021;14:1756284821997794. doi:10.1177/1756284821997794<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/33747126/pubmed" id="33747126" target="_blank">33747126</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31870134">
<a name="31870134"></a>Choi SJ, Oh JS, Hong S, Lee CK, Yoo B, Kim YG. Liver enzyme elevation in patients with ankylosing spondylitis treated with tumor necrosis factor inhibitors: a single-center historical cohort study. <i>Korean J Intern Med</i>. 2020;35(3):723-731. doi:10.3904/kjim.2018.407<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/31870134/pubmed" id="31870134" target="_blank">31870134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19201775">
<a name="19201775"></a>Colombel JF, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. <i>Gut</i>. 2009;58(7):940-948. doi: 10.1136/gut.2008.159251.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/19201775/pubmed" id="19201775" target="_blank">19201775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30289537">
<a name="30289537"></a>Conti F, Atzeni F, Massaro L, et al. The influence of comorbidities on the efficacy of tumour necrosis factor inhibitors, and the effect of tumour necrosis factor inhibitors on comorbidities in rheumatoid arthritis: report from a National Consensus Conference. <i>Rheumatology (Oxford)</i>. 2018;57(57 suppl 7):vii11-vii22. doi:10.1093/rheumatology/key209<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/30289537/pubmed" id="30289537" target="_blank">30289537</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35546331">
<a name="35546331"></a>Coşkun BN, Yağız B, Çorabay SG, Pehlivan Y, Dalkılıç E. Anti-TNF treatment in ankylosing spondylitis patients with chronic kidney disease: Is it effective and safe? <i>Eur J Rheumatol</i>. 2022;9(2):68-74. doi:10.5152/eurjrheum.2022.21099.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/35546331/pubmed" id="35546331" target="_blank">35546331</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32527153">
<a name="32527153"></a>Cossio ML, Genois A, Jantchou P, Hatami A, Deslandres C, McCuaig C. Skin manifestations in pediatric patients treated with a TNF-alpha inhibitor for inflammatory bowel disease: a retrospective study. <i>J Cutan Med Surg</i>. 2020;24(4):333-339. doi:10.1177/1203475420917387<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/32527153/pubmed" id="32527153" target="_blank">32527153</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27215507">
<a name="27215507"></a>Crommelin HA, van der Burg LM, Vorselaars AD, et al. Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab. <i>Respir Med</i>. 2016;115:72-77. doi:10.1016/j.rmed.2016.04.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/27215507/pubmed" id="27215507" target="_blank">27215507</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24093840">
<a name="24093840"></a>Crowson CS, Liao KP, Davis JM 3rd, et al. Rheumatoid arthritis and cardiovascular disease. <i>Am Heart J</i>. 2013;166(4):622-628.e1. doi:10.1016/j.ahj.2013.07.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/24093840/pubmed" id="24093840" target="_blank">24093840</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Boehringer.1">
<a name="Boehringer.1"></a>Cyltezo (adalimumab) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34402108">
<a name="34402108"></a>Cyrenne BM, Parpia AS, Sibbald C. Paradoxical psoriasis in pediatric patients: a systematic review. <i>Pediatr Dermatol</i>. 2021;38(5):1086-1093. doi:10.1111/pde.14712<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/34402108/pubmed" id="34402108" target="_blank">34402108</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28218339">
<a name="28218339"></a>Darrigade AS, Milpied B, Truchetet ME, et al. Pattern and severity of psoriasiform eruptions in patients with inflammatory bowel diseases, arthritis or skin inflammatory disorders treated with TNF-alpha inhibitors. <i>Acta Derm Venereol</i>. 2017;97(6):731-734. doi:10.2340/00015555-2636<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/28218339/pubmed" id="28218339" target="_blank">28218339</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27432853">
<a name="27432853"></a>Davies HD, Committee on Infectious Disease. Infectious complications with the use of biologic response modifiers in infants and children. <i>Pediatrics</i>. 2016;138(2):e20161209.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/27432853/pubmed" id="27432853" target="_blank">27432853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29447652">
<a name="29447652"></a>De Wet J, Jordaan HF, Kannenberg SM, Tod B, Glanzmann B, Visser WI. Pyoderma gangrenosum, acne, and suppurative hidradenitis syndrome in end-stage renal disease successfully treated with adalimumab. <i>Dermatol Online J</i>. 2017;23(12):13030/qt82d4m2zw.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/29447652/pubmed" id="29447652" target="_blank">29447652</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25078637">
<a name="25078637"></a>Drent M, Cremers JP, Jansen TL, Baughman RP. Practical eminence and experience-based recommendations for use of TNF-α inhibitors in sarcoidosis. <i>Sarcoidosis Vasc Diffuse Lung Dis</i>. 2014;31(2):91-107.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/25078637/pubmed" id="25078637" target="_blank">25078637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26950307">
<a name="26950307"></a>Dubinsky MC, Rosh J, Faubion WA Jr, et al. Efficacy and safety of escalation of adalimumab therapy to weekly dosing in pediatric patients with Crohn's disease. <i>Inflamm Bowel Dis</i>. 2016;22(4):886-893.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/26950307/pubmed" id="26950307" target="_blank">26950307</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28211161">
<a name="28211161"></a>Eickstaedt JB, Killpack L, Tung J, Davis D, Hand JL, Tollefson MM. Psoriasis and psoriasiform eruptions in pediatric patients with inflammatory bowel disease treated with anti-tumor necrosis factor alpha agents. <i>Pediatr Dermatol</i>. 2017;34(3):253-260. doi:10.1111/pde.13081<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/28211161/pubmed" id="28211161" target="_blank">28211161</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10843670">
<a name="10843670"></a>Eissner G, Kirchner S, Lindner H, et al. Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages. <i>J Immunol</i>. 2000;164(12):6193-6198. doi:10.4049/jimmunol.164.12.6193<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/10843670/pubmed" id="10843670" target="_blank">10843670</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31921355">
<a name="31921355"></a>Engel S, Luessi F, Mueller A, Schopf RE, Zipp F, Bittner S. PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-α therapy-associated demyelinating disorders. <i>Ther Adv Neurol Disord</i>. 2020;13:1756286419895155. doi:10.1177/1756286419895155<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/31921355/pubmed" id="31921355" target="_blank">31921355</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26965410">
<a name="26965410"></a>Faivre C, Villani AP, Aubin F, et al. Hidradenitis suppurativa (HS): an unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases. <i>J Am Acad Dermatol</i>. 2016;74(6):1153-1159. doi:10.1016/j.jaad.2016.01.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/26965410/pubmed" id="26965410" target="_blank">26965410</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24697221">
<a name="24697221"></a>Fernández-Crehuet P, Ruiz-Villaverde R. Acneiform eruption as a probable paradoxical reaction to adalimumab. <i>Int J Dermatol</i>. 2015;54(8):e306-e308. doi:10.1111/ijd.12416<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/24697221/pubmed" id="24697221" target="_blank">24697221</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25110258">
<a name="25110258"></a>Feuerstein JD, Cheifetz AS. Miscellaneous adverse events with biologic agents (excludes infection and malignancy). <i>Gastroenterol Clin North Am</i>. 2014;43(3):543-563. doi:10.1016/j.gtc.2014.05.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/25110258/pubmed" id="25110258" target="_blank">25110258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34051983">
<a name="34051983"></a>Feuerstein JD, Ho EY, Shmidt E, et al; American Gastroenterological Association Institute Clinical Guidelines Committee. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease. <i>Gastroenterology</i>. 2021;160(7):2496-2508. doi:10.1053/j.gastro.2021.04.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/34051983/pubmed" id="34051983" target="_blank">34051983</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28780013">
<a name="28780013"></a>Feuerstein JD, Nguyen GC, Kupfer SS, Falck-Ytter Y, Singh S; American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease. <i>Gastroenterology.</i> 2017;153(3):827-834. doi: 10.1053/j.gastro.2017.07.032.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/28780013/pubmed" id="28780013" target="_blank">28780013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32981127">
<a name="32981127"></a>Flanagan E, Gibson PR, Wright EK, et al; PICCOLO Study Group. Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure. <i>Aliment Pharmacol Ther</i>. 2020;52(10):1551-1562. doi:10.1111/apt.16102<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/32981127/pubmed" id="32981127" target="_blank">32981127</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34101387">
<a name="34101387"></a>Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. <i>Arthritis Care Res (Hoboken)</i>. 2021;73(7):924-939. doi:10.1002/acr.24596<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/34101387/pubmed" id="34101387" target="_blank">34101387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26692395">
<a name="26692395"></a>French JB, Bonacini M, Ghabril M, Foureau D, Bonkovsky HL. Hepatotoxicity associated with the use of anti-TNF-α agents. <i>Drug Saf</i>. 2016;39(3):199-208. doi:10.1007/s40264-015-0366-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/26692395/pubmed" id="26692395" target="_blank">26692395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25431703">
<a name="25431703"></a>Frider B, Bruno A, Ponte M, Amante M. Drug-induced liver injury caused by adalimumab: a case report and review of the bibliography. <i>Case Reports Hepatol</i>. 2013;2013:406901. doi:10.1155/2013/406901<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/25431703/pubmed" id="25431703" target="_blank">25431703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22858514">
<a name="22858514"></a>Fritzsche J, Pilch A, Mury D, Schaefer C, Weber-Schoendorfer C. Infliximab and adalimumab use during breastfeeding. <i>J Clin Gastroenterol</i>. 2012;46(8):718-719.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/22858514/pubmed" id="22858514" target="_blank">22858514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21339216">
<a name="21339216"></a>Furst DE, Keystone EC, Braun J, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. <i>Ann Rheum Dis</i>. 2011;70(suppl 1):s2-s36. doi:10.1136/ard.2010.146852<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/21339216/pubmed" id="21339216" target="_blank">21339216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17556427">
<a name="17556427"></a>Gallagher M, Quinones K, Cervantes-Castañeda RA, Yilmaz T, Foster CS. Biological response modifier therapy for refractory childhood uveitis.<i> Br J Ophthalmol</i>. 2007;91(10):1341-1344.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/17556427/pubmed" id="17556427" target="_blank">17556427</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23333219">
<a name="23333219"></a>Ghabril M, Bonkovsky HL, Kum C, et al. Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases. <i>Clin Gastroenterol Hepatol</i>. 2013;11(5):558-564.e3. doi:10.1016/j.cgh.2012.12.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/23333219/pubmed" id="23333219" target="_blank">23333219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32889044">
<a name="32889044"></a>Gilotra NA, Wand AL, Pillarisetty A, et al. Clinical and imaging response to tumor necrosis factor alpha inhibitors in treatment of cardiac sarcoidosis: a multicenter experience. <i>J Card Fail.</i> 2021;27(1):83-91. doi:10.1016/j.cardfail.2020.08.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/32889044/pubmed" id="32889044" target="_blank">32889044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31731980">
<a name="31731980"></a>Godfrey MS, Friedman LN. Tuberculosis and biologic therapies: anti-tumor necrosis factor-α and beyond. <i>Clin Chest Med</i>. 2019;40(4):721-739. doi:10.1016/j.ccm.2019.07.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/31731980/pubmed" id="31731980" target="_blank">31731980</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32975341">
<a name="32975341"></a>González-Cuevas R, Peruilh-Bagolini L, Valenzuela F, Vargas-Mora P. Cutaneous lupus erythematosus induced by adalimumab: a case report. <i>Dermatol Ther</i>. 2020;33(6):e14339. doi:10.1111/dth.14339<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/32975341/pubmed" id="32975341" target="_blank">32975341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35718887">
<a name="35718887"></a>Goodman SM, Springer BD, Chen AF, et al. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty. <i>Arthritis Care Res (Hoboken)</i>. 2022;74(9):1399-1408. doi:10.1002/acr.24893<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/35718887/pubmed" id="35718887" target="_blank">35718887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31734937">
<a name="31734937"></a>Grace E, Goldblum O, Renda L, et al. Injection site reactions in the Federal Adverse Event Reporting System (FAERS) post-marketing database vary among biologics approved to treat moderate-to-severe psoriasis. <i>Dermatol Ther (Heidelb)</i>. 2020;10(1):99-106. doi:10.1007/s13555-019-00341-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/31734937/pubmed" id="31734937" target="_blank">31734937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22205272">
<a name="22205272"></a>Grasland A, Sterpu R, Boussoukaya S, Mahe I. Autoimmune hepatitis induced by adalimumab with successful switch to abatacept. <i>Eur J Clin Pharmacol</i>. 2012;68(5):895-898. doi:10.1007/s00228-011-1191-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/22205272/pubmed" id="22205272" target="_blank">22205272</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22056398">
<a name="22056398"></a>Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. <i>JAMA</i>. 2011;306(21):2331-2339. doi:10.1001/jama.2011.1692<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/22056398/pubmed" id="22056398" target="_blank">22056398</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gulsen.1">
<a name="Gulsen.1"></a>Gulsen A, Wedi B, Jappe U. Hypersensitivity reactions to biologics (part II): classifications and current diagnostic and treatment approaches. <i>Allergo J Int</i>. 2020;29:139-154. doi:10.1007/s40629-020-00127-5</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hadlima.2">
<a name="Hadlima.2"></a>Hadlima (adalimumab-bwwd) [prescribing information]. Jersey City, NJ: Organon LLC; July 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hadlima.1">
<a name="Hadlima.1"></a>Hadlima and Hadlima PushTouch (adalimumab) [product monograph]. Kirkland, Quebec, Canada: Organon Canada Inc; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33105057">
<a name="33105057"></a>Hammam N, Evans M, Morgan E, et al. Treatment of sarcoidosis in US rheumatology practices: data from the American College of Rheumatology's Rheumatology Informatics System for Effectiveness (RISE) Registry. <i>Arthritis Care Res (Hoboken).</i> 2022;74(3):371-376. doi:10.1002/acr.24496<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/33105057/pubmed" id="33105057" target="_blank">33105057</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16981296">
<a name="16981296"></a>Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. <i>J Rheumatol</i>. 2006;33(11):2167-2172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/16981296/pubmed" id="16981296" target="_blank">16981296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30006049">
<a name="30006049"></a>Hansel K, Bianchi L, Tramontana M, et al. Immediate local and systemic hypersensitivity due to etanercept and adalimumab. <i>J Allergy Clin Immunol Pract</i>. 2019;7(2):726-727. doi:10.1016/j.jaip.2018.06.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/30006049/pubmed" id="30006049" target="_blank">30006049</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22515220">
<a name="22515220"></a>Hawryluk EB, Linskey KR, Duncan LM, Nazarian RM. Broad range of adverse cutaneous eruptions in patients on TNF-alpha antagonists. <i>J Cutan Pathol</i>. 2012;39(5):481-492. doi:10.1111/j.1600-0560.2012.01894.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/22515220/pubmed" id="22515220" target="_blank">22515220</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26768759">
<a name="26768759"></a>Her M, Kavanaugh A. Alterations in immune function with biologic therapies for autoimmune disease. <i>J Allergy Clin Immunol</i>. 2016;137(1):19-27. doi:10.1016/j.jaci.2015.10.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/26768759/pubmed" id="26768759" target="_blank">26768759</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9345421">
<a name="9345421"></a>Hohlfeld R. Inhibitors of tumor necrosis factor-alpha: promising agents for the treatment of multiple sclerosis? <i>Mult Scler</i>. 1996;1(6):376-378. doi:10.1177/135245859600100619<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/9345421/pubmed" id="9345421" target="_blank">9345421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17337474">
<a name="17337474"></a>Hueber AJ, Tunc A, Schett G, Manger B. Anti-tumour necrosis factor alpha therapy in patients with impaired renal function. <i>Ann Rheum Dis</i>. 2007;66(7):981-982. doi:10.1136/ard.2006.069211<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/17337474/pubmed" id="17337474" target="_blank">17337474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hulio.2">
<a name="Hulio.2"></a>Hulio (adalimumab-fkjp) [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hulio.1">
<a name="Hulio.1"></a>Hulio (adalimumab) [product monograph]. Etobicoke, Ontario, Canada: BGP Pharma ULC; July 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Humira.1">
<a name="Humira.1"></a>Humira (adalimumab) [prescribing information]. North Chicago, IL: AbbVie Inc; November 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Humira.3">
<a name="Humira.3"></a>Humira (adalimumab) [product monograph]. St-Laurent, Quebec, Canada: AbbVie Corporation; March 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Humira.2">
<a name="Humira.2"></a>Humira (adalimumab) [product monograph]. St-Laurent, Quebec, Canada: AbbVie Corporation; September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33945946">
<a name="33945946"></a>Hutto SK, Rice DR, Mateen FJ. CNS demyelination with TNFα inhibitor exposure: a retrospective cohort study. <i>J Neuroimmunol</i>. 2021;356:577587. doi:10.1016/j.jneuroim.2021.577587<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/33945946/pubmed" id="33945946" target="_blank">33945946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22562021">
<a name="22562021"></a>Hyams JS, Griffiths A, Markowitz J, et al. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children. <i>Gastroenterology</i>. 2012;143(2):365-374.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/22562021/pubmed" id="22562021" target="_blank">22562021</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hyrimoz.2">
<a name="Hyrimoz.2"></a>Hyrimoz (adalimumab-adaz) [prescribing information]. Princeton, NJ: Sandoz Inc; September 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hyrimoz.1">
<a name="Hyrimoz.1"></a>Hyrimoz (adalimumab) [product monograph]. Boucherville, Québec, Canada: Sandoz Canada Inc; September 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Idacio.2">
<a name="Idacio.2"></a>Idacio (adalimumab) [prescribing information]. Lake Zurich, IL: Fresenius Kabi USA LLC; October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Idacio.1">
<a name="Idacio.1"></a>Idacio (adalimumab) [product monograph]. Toronto, Ontario, Canada: Fresenius Kabi Canada Ltd; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ingram.1">
<a name="Ingram.1"></a>Ingram JR. Hidradenitis suppurativa: management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed July 19, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27777187">
<a name="27777187"></a>Inoue A, Sawada Y, Yamaguchi T, et al. Lichenoid drug eruption caused by adalimumab: a case report and literature review. <i>Eur J Dermatol</i>. 2017;27(1):69-70. doi:10.1684/ejd.2016.2898<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/27777187/pubmed" id="27777187" target="_blank">27777187</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23557269">
<a name="23557269"></a>Juhász K, Buzás K, Duda E. Importance of reverse signaling of the TNF superfamily in immune regulation. <i>Expert Rev Clin Immunol</i>. 2013;9(4):335-348. doi:10.1586/eci.13.14<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/23557269/pubmed" id="23557269" target="_blank">23557269</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27063728">
<a name="27063728"></a>Julsgaard M, Christensen LA, Gibson PR, et al. Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection. <i>Gastroenterology</i>. 2016;151(1):110-119.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/27063728/pubmed" id="27063728" target="_blank">27063728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31845616">
<a name="31845616"></a>Kalinowska-Lyszczarz A, Fereidan-Esfahani M, Guo Y, Lucchinetti CF, Tobin WO. Pathological findings in central nervous system demyelination associated with infliximab. <i>Mult Scler</i>. 2020;26(9):1124-1129. doi:10.1177/1352458519894710<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/31845616/pubmed" id="31845616" target="_blank">31845616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25739794">
<a name="25739794"></a>Kelly D, O'Connell O, Henry M. Adalimumab-induced lupus serositis. <i>BMJ Case Rep</i>. 2015;2015:bcr2014207323. Published 2015 Mar 4. doi:10.1136/bcr-2014-207323<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/25739794/pubmed" id="25739794" target="_blank">25739794</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28337644">
<a name="28337644"></a>Kemanetzoglou E, Andreadou E. CNS Demyelination with TNF-α Blockers. <i>Curr Neurol Neurosci Rep</i>. 2017;17(4):36. doi:10.1007/s11910-017-0742-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/28337644/pubmed" id="28337644" target="_blank">28337644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24179620">
<a name="24179620"></a>Kim E, Bressler B, Schaeffer DF, Yoshida EM. Severe cholestasis due to adalimumab in a Crohn's disease patient. <i>World J Hepatol</i>. 2013;5(10):592-595. doi:10.4254/wjh.v5.i10.592<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/24179620/pubmed" id="24179620" target="_blank">24179620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27518661">
<a name="27518661"></a>Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. <i>N Engl J Med</i>. 2016;375(5):422-434. doi:10.1056/NEJMoa1504370<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/27518661/pubmed" id="27518661" target="_blank">27518661</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24487484">
<a name="24487484"></a>Kingsbury DJ, Bader-Meunier B, Patel G, et al. Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years. <i>Clin Rheumatol</i>. 2014;33(10):1433–1441.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/24487484/pubmed" id="24487484" target="_blank">24487484</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20472597">
<a name="20472597"></a>Klarenbeek NB, van der Kooij SM, Huizinga TJ, et al. Blood pressure changes in patients with recent-onset rheumatoid arthritis treated with four different treatment strategies: a post hoc analysis from the BeSt trial. <i>Ann Rheum Dis</i>. 2010;69(7):1342-1345. doi:10.1136/ard.2009.124180<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/20472597/pubmed" id="20472597" target="_blank">20472597</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20340019">
<a name="20340019"></a>Kobak S. Efficacy and safety of adalimumab in a patient with ankylosing spondylitis on peritoneal dialysis. <i>Rheumatol Int</i>. 2012;32(6):1785-1787. doi:10.1007/s00296-010-1457-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/20340019/pubmed" id="20340019" target="_blank">20340019</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29564668">
<a name="29564668"></a>Kok B, Lester ELW, Lee WM, et al. Acute liver failure from tumor necrosis factor-α antagonists: report of four cases and literature review. <i>Dig Dis Sci</i>. 2018;63(6):1654-1666. doi:10.1007/s10620-018-5023-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/29564668/pubmed" id="29564668" target="_blank">29564668</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28652663">
<a name="28652663"></a>Koller T, Galambosova M, Filakovska S, et al. Drug-induced liver injury in inflammatory bowel disease: 1-year prospective observational study. <i>World J Gastroenterol</i>. 2017;23(22):4102-4111. doi:10.3748/wjg.v23.i22.4102<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/28652663/pubmed" id="28652663" target="_blank">28652663</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29895751">
<a name="29895751"></a>Kotyla PJ. Bimodal function of anti-TNF treatment: shall we be concerned about anti-TNF treatment in patients with rheumatoid arthritis and heart failure? <i>Int J Mol Sci</i>. 2018;19(6):1739. doi:10.3390/ijms19061739<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/29895751/pubmed" id="29895751" target="_blank">29895751</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30767720">
<a name="30767720"></a>Kumar N, Abboud H. Iatrogenic CNS demyelination in the era of modern biologics. <i>Mult Scler</i>. 2019;25(8):1079-1085. doi:10.1177/1352458519828601<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/30767720/pubmed" id="30767720" target="_blank">30767720</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32421186">
<a name="32421186"></a>Kunchok A, Aksamit AJ Jr, Davis JM 3rd, et al. Association between tumor necrosis factor inhibitor exposure and inflammatory central nervous system events. <i>JAMA Neurol</i>. 2020;77(8):937-946. doi:10.1001/jamaneurol.2020.1162<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/32421186/pubmed" id="32421186" target="_blank">32421186</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25916786">
<a name="25916786"></a>Kusakari Y, Yamasaki K, Takahashi T, et al. Successful adalimumab treatment of a psoriasis vulgaris patient with hemodialysis for renal failure: a case report and a review of the previous reports on biologic treatments for psoriasis patients with hemodialysis for renal failure. <i>J Dermatol</i>. 2015;42(7):727-730. doi:10.1111/1346-8138.12901<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/25916786/pubmed" id="25916786" target="_blank">25916786</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12755552">
<a name="12755552"></a>Kwon HJ, Coté TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. <i>Ann Intern Med</i>. 2003;138(10):807-811. doi:10.7326/0003-4819-138-10-200305200-00008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/12755552/pubmed" id="12755552" target="_blank">12755552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29507939">
<a name="29507939"></a>Labetoulle R, Roblin X, Paul S. Prolonged persistence of adalimumab transferred from mother to infant during pregnancy. <i>Ann Intern Med</i>. 2018;169(1):60-61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/29507939/pubmed" id="29507939" target="_blank">29507939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21719446">
<a name="21719446"></a>Lan JL, Chen YM, Hsieh TY, et al. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. <i>Ann Rheum Dis</i>. 2011;70(10):1719-1725. doi:10.1136/ard.2010.148783<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/21719446/pubmed" id="21719446" target="_blank">21719446</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24244376">
<a name="24244376"></a>Latus J, Klein R, Koetter I, et al. Cholestatic liver disease after rituximab and adalimumab and the possible role of cross-reacting antibodies to Fab 2 fragments. <i>PLoS One</i>. 2013;8(11):e78856. doi:10.1371/journal.pone.0078856<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/24244376/pubmed" id="24244376" target="_blank">24244376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34427860">
<a name="34427860"></a>Lau G, Yu ML, Wong G, et al. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. <i>Hepatol Int</i>. 2021;15(5):1031-1048. doi:10.1007/s12072-021-10239-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/34427860/pubmed" id="34427860" target="_blank">34427860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18753157">
<a name="18753157"></a>Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. <i>Ann Rheum Dis</i>. 2009;68(7):1136-1145. doi:10.1136/ard.2008.091025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/18753157/pubmed" id="18753157" target="_blank">18753157</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29175008">
<a name="29175008"></a>Li PH, Watts TJ, Lui MS, Lau CS, Chung HY. Recall urticaria in adalimumab hypersensitivity. <i>J Allergy Clin Immunol Pract</i>. 2018;6(3):1032-1033. doi:10.1016/j.jaip.2017.10.031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/29175008/pubmed" id="29175008" target="_blank">29175008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31093599">
<a name="31093599"></a>Li SJ, Perez-Chada LM, Merola JF. TNF Inhibitor-induced psoriasis: proposed algorithm for treatment and management. <i>J Psoriasis Psoriatic Arthritis</i>. 2019;4(2):70-80. doi:10.1177/2475530318810851<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/31093599/pubmed" id="31093599" target="_blank">31093599</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29610508">
<a name="29610508"></a>Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn's disease in adults. <i>Am J Gastroenterol</i>. 2018;113(4):481-517. doi: 10.1038/ajg.2018.27.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/29610508/pubmed" id="29610508" target="_blank">29610508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25756476">
<a name="25756476"></a>Lieberman MR, Liebman TN, Alapati U, Khachemoune A. TNF-inhibitor induced lupus in a patient treated with adalimumab for rheumatoid arthritis. <i>Dermatol Online J</i>. 2014;21(2):13030/qt18r2916d.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/25756476/pubmed" id="25756476" target="_blank">25756476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lok.1">
<a name="Lok.1"></a>Lok ASF, Bonis PAL. Hepatitis B virus reactivation associated with immunosuppressive therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed September 31, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28219691">
<a name="28219691"></a>Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. <i>Gastroenterology</i>. 2017;152(6):1297-1309. doi:10.1053/j.gastro.2017.02.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/28219691/pubmed" id="28219691" target="_blank">28219691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18716298">
<a name="18716298"></a>Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. <i>N Engl J Med.</i> 2008;359(8):810-820.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/18716298/pubmed" id="18716298" target="_blank">18716298</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31820728">
<a name="31820728"></a>Lower EE, Sturdivant M, Grate L, Baughman RP. Use of third-line therapies in advanced sarcoidosis. <i>Clin Exp Rheumatol.</i> 2020;38(5):834-840.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/31820728/pubmed" id="31820728" target="_blank">31820728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mahadevan.1">
<a name="Mahadevan.1"></a>Mahadevan U, Martin CF, Sandler RS et al. PIANO: A 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy. <i>Gastroenterology</i>. 2012;142 (Suppl 1):S149.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30948039">
<a name="30948039"></a>Mahadevan U, Robinson C, Bernasko N, et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD Parenthood Project Working Group. <i>Am J Obstet Gynecol</i>. 2019;220(4):308-323. doi:10.1016/j.ajog.2019.02.027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/30948039/pubmed" id="30948039" target="_blank">30948039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23200982">
<a name="23200982"></a>Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. <i>Clin Gastroenterol Hepatol</i>. 2013;11(3):286-92; quiz e24. doi:10.1016/j.cgh.2012.11.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/23200982/pubmed" id="23200982" target="_blank">23200982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33563886">
<a name="33563886"></a>Mansitó López C, Torres Laboy P, Ortiz Bou M, Quintero Noriega A, Cintron Rivera V. Fatal new-onset congestive heart failure related to adalimumab use in a patient with relapsing hidradenitis suppurativa: a case report. <i>Am J Case Rep</i>. 2021;22:e929148. doi:10.12659/AJCR.929148<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/33563886/pubmed" id="33563886" target="_blank">33563886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26422518">
<a name="26422518"></a>Marzano AV, Tavecchio S, Berti E, Gelmetti C, Cugno M. Pustular skin reaction to tumor necrosis factor alpha antagonists in patients with inflammatory bowel diseases. <i>Inflamm Bowel Dis</i>. 2015;21(11):E26-E27. doi:10.1097/MIB.0000000000000600<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/26422518/pubmed" id="26422518" target="_blank">26422518</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19505409">
<a name="19505409"></a>Massarotti M, Marasini B. Successful treatment with etanercept of a patient with psoriatic arthritis after adalimumab-related hepatotoxicity. <i>Int J Immunopathol Pharmacol</i>. 2009;22(2):547-549. doi:10.1177/039463200902200234<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/19505409/pubmed" id="19505409" target="_blank">19505409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29857090">
<a name="29857090"></a>Matro R, Martin CF, Wolf D, Shah SA, Mahadevan U. Exposure concentrations of infants breastfed by women receiving biologic therapies for inflammatory bowel diseases and effects of breastfeeding on infections and development. <i>Gastroenterology</i>. 2018;155(3):696-704.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/29857090/pubmed" id="29857090" target="_blank">29857090</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28260984">
<a name="28260984"></a>Matsui T, Umetsu R, Kato Y, et al. Age-related trends in injection site reaction incidence induced by the tumor necrosis factor-α (TNF-α) inhibitors etanercept and adalimumab: the Food and Drug Administration adverse event reporting system, 2004-2015. <i>Int J Med Sci</i>. 2017;14(2):102-109. doi:10.7150/ijms.17025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/28260984/pubmed" id="28260984" target="_blank">28260984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25545240">
<a name="25545240"></a>Mease P, Sieper J, Van den Bosch F, Rahman P, Karunaratne PM, Pangan AL. Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis. <i>Arthritis Rheumatol</i>. 2015;67(4):914-923. doi:10.1002/art.39008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/25545240/pubmed" id="25545240" target="_blank">25545240</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34143362">
<a name="34143362"></a>Melani AS, Bigliazzi C, Cimmino FA, Bergantini L, Bargagli E. A comprehensive review of sarcoidosis treatment for pulmonologists. <i>Pulm Ther.</i> 2021;7(2):325-344. doi:10.1007/s41030-021-00160-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/34143362/pubmed" id="34143362" target="_blank">34143362</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30028008">
<a name="30028008"></a>Melo FJ, Magina S. Clinical management of Anti-TNF-alpha-induced psoriasis or psoriasiform lesions in inflammatory bowel disease patients: a systematic review. <i>Int J Dermatol</i>. 2018;57(12):1521-1532. doi:10.1111/ijd.14072<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/30028008/pubmed" id="30028008" target="_blank">30028008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30772098">
<a name="30772098"></a>Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.<i> J Am Acad Dermatol</i>. 2019;80(4):1029-1072. doi:10.1016/j.jaad.2018.11.057<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/30772098/pubmed" id="30772098" target="_blank">30772098</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24685910">
<a name="24685910"></a>Mercer LK, Lunt M, Low AL, et al. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Ann Rheum Dis</i>. 2015;74(6):1087-1093. doi:10.1136/annrheumdis-2013-204851<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/24685910/pubmed" id="24685910" target="_blank">24685910</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23453887">
<a name="23453887"></a>Mocci G, Marzo M, Papa A, Armuzzi A, Guidi L. Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease. <i>J Crohns Colitis</i>. 2013;7(10):769-779. doi:10.1016/j.crohns.2013.01.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/23453887/pubmed" id="23453887" target="_blank">23453887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11762947">
<a name="11762947"></a>Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. <i>Arthritis Rheum</i>. 2001;44(12):2862-2869. doi:10.1002/1529-0131(200112)44:12&lt;2862::aid-art474&gt;3.0.co;2-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/11762947/pubmed" id="11762947" target="_blank">11762947</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34625145">
<a name="34625145"></a>Montolio Chiva L, Martínez Ferrer À, Mateu Puchades A, Campos Fernández C, Narváez Garcia J, Alegre Sancho JJ. Psoriasis induced by biological therapy. <i>Reumatol Clin (Engl Ed)</i>. 2021;17(8):437-439. doi:10.1016/j.reumae.2020.06.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/34625145/pubmed" id="34625145" target="_blank">34625145</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22187054">
<a name="22187054"></a>Mounach A, Rezqi A, Nouijai A, et al. Stevens-Johnson syndrome complicating adalimumab therapy in rheumatoid arthritis disease. <i>Rheumatol Int</i>. 2013;33(5):1351-1353. doi:10.1007/s00296-011-2212-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/22187054/pubmed" id="22187054" target="_blank">22187054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19628303">
<a name="19628303"></a>Moustou AE, Matekovits A, Dessinioti C, Antoniou C, Sfikakis PP, Stratigos AJ. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. <i>J Am Acad Dermatol</i>. 2009;61(3):486-504. doi:10.1016/j.jaad.2008.10.060<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/19628303/pubmed" id="19628303" target="_blank">19628303</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26559805">
<a name="26559805"></a>Murdaca G, Spanò F, Contatore M, et al. Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety? <i>Expert Opin Drug Saf</i>. 2016;15(1):43-52. doi:10.1517/14740338.2016.1112375<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/26559805/pubmed" id="26559805" target="_blank">26559805</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23330811">
<a name="23330811"></a>Murdaca G, Spanò F, Puppo F. Selective TNF-α inhibitor-induced injection site reactions. <i>Expert Opin Drug Saf</i>. 2013;12(2):187-193. doi:10.1517/14740338.2013.755957<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/23330811/pubmed" id="23330811" target="_blank">23330811</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21216812">
<a name="21216812"></a>Myasoedova E, Crowson CS, Kremers HM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. <i>Ann Rheum Dis</i>. 2011;70(3):482-487. doi:10.1136/ard.2010.135871<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/21216812/pubmed" id="21216812" target="_blank">21216812</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25284873">
<a name="25284873"></a>Nakamizo S, Miyachi Y, Kabashima K. Addition of cyclosporine to adalimumab improved psoriasis and adalimumab-induced injection site reaction. <i>Indian J Dermatol</i>. 2014;59(5):522-523. doi:10.4103/0019-5154.139924<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/25284873/pubmed" id="25284873" target="_blank">25284873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25609412">
<a name="25609412"></a>Navarro-Millán I, Yang S, DuVall SL, et al. Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health Administration. <i>Ann Rheum Dis</i>. 2016;75(2):341-347. doi:10.1136/annrheumdis-2013-204987<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/25609412/pubmed" id="25609412" target="_blank">25609412</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31290151">
<a name="31290151"></a>Neves JM, Cunha N, Lencastre A, Cabete J. Paradoxical hidradenitis suppurativa to biologic agents: a case series and literature review. <i>Int J Dermatol</i>. 2019;58(11):e226-e228. doi:10.1111/ijd.14585<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/31290151/pubmed" id="31290151" target="_blank">31290151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27840074">
<a name="27840074"></a>Nguyen GC, Loftus EV Jr, Hirano I, Falck-Ytter Y, Singh S, Sultan S; AGA Institute Clinical Guidelines Committee. American Gastroenterological Association Institute guideline on the management of Crohn's disease after surgical resection. <i>Gastroenterology</i>. 2017;152(1):271-275. doi:10.1053/j.gastro.2016.10.038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/27840074/pubmed" id="27840074" target="_blank">27840074</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15692992">
<a name="15692992"></a>Nicola PJ, Maradit-Kremers H, Roger VL, et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. <i>Arthritis Rheum</i>. 2005;52(2):412-420. doi:10.1002/art.20855<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/15692992/pubmed" id="15692992" target="_blank">15692992</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32931960">
<a name="32931960"></a>Nielsen OH, Gubatan JM, Juhl CB, Streett SE, Maxwell C. Biologics for inflammatory bowel disease and their safety in pregnancy: a systematic review and meta-analysis. <i>Clin Gastroenterol Hepatol.</i> 2020:S1542-3565(20)31281-31287. doi:10.1016/j.cgh.2020.09.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/32931960/pubmed" id="32931960" target="_blank">32931960</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. <i>Clin Dev Immunol</i>. 2012;2012:985646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18794465">
<a name="18794465"></a>Paltiel M, Gober LM, Deng A, et al. Immediate type I hypersensitivity response implicated in worsening injection site reactions to adalimumab. <i>Arch Dermatol</i>. 2008;144(9):1190-1194. doi:10.1001/archderm.144.9.1190<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/18794465/pubmed" id="18794465" target="_blank">18794465</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23139265">
<a name="23139265"></a>Paramarta JE, De Rycke L, Heijda TF, et al. Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis. <i>Ann Rheum Dis</i>. 2013;72(11):1793-1799. doi:10.1136/annrheumdis-2012-202245<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/23139265/pubmed" id="23139265" target="_blank">23139265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24707412">
<a name="24707412"></a>Parekh R, Kaur N. Liver injury secondary to anti-TNF-alpha therapy in inflammatory bowel disease: a case series and review of the literature. <i>Case Rep Gastrointest Med</i>. 2014;2014:956463. doi:10.1155/2014/956463<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/24707412/pubmed" id="24707412" target="_blank">24707412</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23276549">
<a name="23276549"></a>Pariser RJ, Paul J, Hirano S, Torosky C, Smith M. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. <i>J Am Acad Dermatol.</i> 2013;68(5):765-773. doi:10.1016/j.jaad.2012.10.056<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/23276549/pubmed" id="23276549" target="_blank">23276549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32357984">
<a name="32357984"></a>Pasadyn SR, Knabel D, Fernandez AP, Warren CB. Cutaneous adverse effects of biologic medications. <i>Cleve Clin J Med</i>. 2020;87(5):288-299. doi:10.3949/ccjm.87a.19119<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/32357984/pubmed" id="32357984" target="_blank">32357984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod Toxicol</i>. 2009;86(4):328-344.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28110056">
<a name="28110056"></a>Picard M, Galvão VR. Current knowledge and management of hypersensitivity reactions to monoclonal antibodies. <i>J Allergy Clin Immunol Pract</i>. 2017;5(3):600-609. doi:10.1016/j.jaip.2016.12.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/28110056/pubmed" id="28110056" target="_blank">28110056</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26235565">
<a name="26235565"></a>Pugliese D, Guidi L, Ferraro PM, et al. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study. <i>Aliment Pharmacol Ther</i>. 2015;42(7):880-888. doi:10.1111/apt.13352<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/26235565/pubmed" id="26235565" target="_blank">26235565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22289732">
<a name="22289732"></a>Puxeddu I, Giori L, Rocchi V, et al. Hypersensitivity reactions during treatment with infliximab, etanercept, and adalimumab. <i>Ann Allergy Asthma Immunol</i>. 2012;108(2):123-124. doi:10.1016/j.anai.2011.11.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/22289732/pubmed" id="22289732" target="_blank">22289732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25107559">
<a name="25107559"></a>Raaschou P, Frisell T, Askling J; ARTIS Study Group. TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study. <i>Ann Rheum Dis</i>. 2015;74(12):2137-2143. doi:10.1136/annrheumdis-2014-205745<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/25107559/pubmed" id="25107559" target="_blank">25107559</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28543445">
<a name="28543445"></a>Rademaker M, Agnew K, Andrews M, et al. Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration. <i>Australas J Dermatol</i>. 2018;59(2):86-100.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/28543445/pubmed" id="28543445" target="_blank">28543445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17632266">
<a name="17632266"></a>Ramos-Casals M, Brito-Zerón P, Muñoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. <i>Medicine (Baltimore)</i>. 2007;86(4):242-251. doi:10.1097/MD.0b013e3181441a68<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/17632266/pubmed" id="17632266" target="_blank">17632266</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19854301">
<a name="19854301"></a>Ramos-Casals M, Roberto-Perez-Alvarez, Diaz-Lagares C, Cuadrado MJ, Khamashta MA; BIOGEAS Study Group. Autoimmune diseases induced by biological agents: a double-edged sword? <i>Autoimmun Rev</i>. 2010;9(3):188-193. doi:10.1016/j.autrev.2009.10.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/19854301/pubmed" id="19854301" target="_blank">19854301</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26140007">
<a name="26140007"></a>Rodrigues S, Lopes S, Magro F, et al. Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: a single center report of 8 cases. <i>World J Gastroenterol</i>. 2015;21(24):7584-7588. doi:10.3748/wjg.v21.i24.7584<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/26140007/pubmed" id="26140007" target="_blank">26140007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15767026">
<a name="15767026"></a>Rubin RL. Drug-induced lupus. <i>Toxicology</i>. 2005;209(2):135-147. doi:10.1016/j.tox.2004.12.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/15767026/pubmed" id="15767026" target="_blank">15767026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29593717">
<a name="29593717"></a>Salomon BL, Leclerc M, Tosello J, Ronin E, Piaggio E, Cohen JL. Tumor necrosis factor α and regulatory T cells in oncoimmunology. <i>Front Immunol</i>. 2018;9:444. doi:10.3389/fimmu.2018.00444<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/29593717/pubmed" id="29593717" target="_blank">29593717</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32135533">
<a name="32135533"></a>Salvador-Rodriguez L, Montero-Vílchez T, Arias-Santiago S, Molina-Leyva A. Paradoxical hidradenitis suppurativa in patients receiving TNF-α inhibitors: case series, systematic review, and case meta-analysis. <i>Dermatology</i>. 2020;236(4):307-313. doi:10.1159/000506074<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/32135533/pubmed" id="32135533" target="_blank">32135533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16439435">
<a name="16439435"></a>Schiff MH, Burmester GR, Kent JD, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. <i>Ann Rheum Dis</i>. 2006;65(7):889-894. doi:10.1136/ard.2005.043166<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/16439435/pubmed" id="16439435" target="_blank">16439435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25169849">
<a name="25169849"></a>Sedger LM, McDermott MF. TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants - past, present and future. <i>Cytokine Growth Factor Rev</i>. 2014;25(4):453-472. doi:10.1016/j.cytogfr.2014.07.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/25169849/pubmed" id="25169849" target="_blank">25169849</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28318043">
<a name="28318043"></a>Seow CH, Leung Y, Vande Casteele N, et al. The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease. <i>Aliment Pharmacol Ther</i>. 2017;45(10):1329-1338.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/28318043/pubmed" id="28318043" target="_blank">28318043</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23287362">
<a name="23287362"></a>Seror R, Richez C, Sordet C, et al. Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey. <i>Rheumatology (Oxford)</i>. 2013;52(5):868-874. doi:10.1093/rheumatology/kes375<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/23287362/pubmed" id="23287362" target="_blank">23287362</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32025603">
<a name="32025603"></a>Shah P, Sundaram V, Björnsson E. Biologic and checkpoint inhibitor-induced liver injury: a systematic literature review. <i>Hepatol Commun</i>. 2020;4(2):172-184. doi:10.1002/hep4.1465<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/32025603/pubmed" id="32025603" target="_blank">32025603</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25756190">
<a name="25756190"></a>Shelton E, Chaudrey K, Sauk J, et al. New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease. <i>Aliment Pharmacol Ther</i>. 2015;41(10):972-979. doi:10.1111/apt.13159<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/25756190/pubmed" id="25756190" target="_blank">25756190</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22772328">
<a name="22772328"></a>Sieper J, van der Heijde D, Dougados M, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). <i>Ann Rheum Dis</i>. 2013;72(6):815-822. doi:10.1136/annrheumdis-2012-201766<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/22772328/pubmed" id="22772328" target="_blank">22772328</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Simlandi.1">
<a name="Simlandi.1"></a>Simlandi (adalimumab) [product monograph]. Boucherville, Quebec, Canada: Pfizer Canada ULC; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21452272">
<a name="21452272"></a>Simonini G, Taddio A, Cattalini M, et al. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. <i>Arthritis Care Res (Hoboken)</i>. 2011;63(4):612-618. doi:10.1002/acr.20404<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/21452272/pubmed" id="21452272" target="_blank">21452272</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22473917">
<a name="22473917"></a>Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. <i>Arthritis Care Res (Hoboken).</i> 2012;64(5):625-639. doi:10.1002/acr.21641<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/22473917/pubmed" id="22473917" target="_blank">22473917</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21328309">
<a name="21328309"></a>Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. <i>Cochrane Database Syst Rev</i>. 2011;2011(2):CD008794. doi:10.1002/14651858.CD008794.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/21328309/pubmed" id="21328309" target="_blank">21328309</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30876964">
<a name="30876964"></a>Singh S, Facciorusso A, Dulai PS, Jairath V, Sandborn WJ. Comparative risk of serious infections with biologic and/or immunosuppressive therapy in patients with inflammatory bowel diseases: a systematic review and meta-analysis. <i>Clin Gastroenterol Hepatol</i>. 2020;18(1):69-81.e3. doi:10.1016/j.cgh.2019.02.044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/30876964/pubmed" id="30876964" target="_blank">30876964</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25776112">
<a name="25776112"></a>Solomon DH, Reed GW, Kremer JM, et al. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. <i>Arthritis Rheumatol</i>. 2015;67(6):1449-1455. doi:10.1002/art.39098<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/25776112/pubmed" id="25776112" target="_blank">25776112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29718343">
<a name="29718343"></a>Sridhar S, Maltz RM, Boyle B, Kim SC. Dermatological manifestations in pediatric patients with inflammatory bowel diseases on anti-TNF therapy. <i>Inflamm Bowel Dis</i>. 2018;24(9):2086-2092. doi:10.1093/ibd/izy112<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/29718343/pubmed" id="29718343" target="_blank">29718343</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22261535">
<a name="22261535"></a>Steenholdt C, Svenson M, Bendtzen K, Thomsen OØ, Brynskov J, Ainsworth MA. Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease. <i>J Crohns Colitis</i>. 2012;6(1):108-111. doi:10.1016/j.crohns.2011.08.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/22261535/pubmed" id="22261535" target="_blank">22261535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21535447">
<a name="21535447"></a>Steenholdt C, Svenson M, Bendtzen K, Thomsen OØ, Brynskov J, Ainsworth MA. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. <i>Aliment Pharmacol Ther</i>. 2011;34(1):51-58. doi:10.1111/j.1365-2036.2011.04682.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/21535447/pubmed" id="21535447" target="_blank">21535447</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21791449">
<a name="21791449"></a>Strangfeld A, Eveslage M, Schneider M, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? <i>Ann Rheum Dis</i>. 2011;70(11):1914-1920. doi:10.1136/ard.2011.151043<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/21791449/pubmed" id="21791449" target="_blank">21791449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20064207">
<a name="20064207"></a>Strangfeld A, Hierse F, Rau R, et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. <i>Arthritis Res Ther</i>. 2010;12(1):R5. doi:10.1186/ar2904<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/20064207/pubmed" id="20064207" target="_blank">20064207</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22807318">
<a name="22807318"></a>Sumida K, Ubara Y, Suwabe T, et al. Adalimumab treatment in patients with rheumatoid arthritis with renal insufficiency. <i>Arthritis Care Res (Hoboken)</i>. 2013;65(3):471-475. doi:10.1002/acr.21800<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/22807318/pubmed" id="22807318" target="_blank">22807318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24751453">
<a name="24751453"></a>Sweiss NJ, Noth I, Mirsaeidi M, et al. Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis.<i> Sarcoidosis Vasc Diffuse Lung Dis.</i> 2014;31(1):46-54.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/24751453/pubmed" id="24751453" target="_blank">24751453</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33863839">
<a name="33863839"></a>Taylor TRP, Galloway J, Davies R, Hyrich K, Dobson R. Demyelinating events following initiation of anti-TNFα therapy in the British Society for Rheumatology Biologics Registry in Rheumatoid Arthritis. <i>Neurol Neuroimmunol Neuroinflamm</i>. 2021;8(3):e992. doi:10.1212/NXI.0000000000000992<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/33863839/pubmed" id="33863839" target="_blank">33863839</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29405329">
<a name="29405329"></a>Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. <i>Hepatology</i>. 2018;67(4):1560-1599. doi:10.1002/hep.29800<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/29405329/pubmed" id="29405329" target="_blank">29405329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rosenbaum.1">
<a name="Rosenbaum.1"></a>Thorne JE. Uveitis: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed May 24, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22662786">
<a name="22662786"></a>Titos Arcos JC, Hallal H, Robles M, Andrade RJ. Recurrent hepatotoxicity associated with etanercept and adalimumab but not with infliximab in a patient with rheumatoid arthritis. <i>Rev Esp Enferm Dig</i>. 2012;104(5):282-284. doi:10.4321/s1130-01082012000500014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/22662786/pubmed" id="22662786" target="_blank">22662786</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30044357">
<a name="30044357"></a>Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of paediatric ulcerative colitis, part 1: ambulatory care-an evidence-based guideline from European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. <i>J Pediatr Gastroenterol Nutr</i>. 2018;67(2):257-291.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/30044357/pubmed" id="30044357" target="_blank">30044357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin Pharmacokinet</i>. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33026087">
<a name="33026087"></a>van Rheenen PF, Aloi M, Assa A, et al. The medical management of paediatric Crohn's disease: an ECCO-ESPGHAN guideline update. <i>J Crohns Colitis</i>. Published online October 7, 2020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/33026087/pubmed" id="33026087" target="_blank">33026087</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12851868">
<a name="12851868"></a>Vermeire S, Noman M, Van Assche G, et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. <i>Gastroenterology</i>. 2003;125(1):32-39. doi:10.1016/s0016-5085(03)00701-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/12851868/pubmed" id="12851868" target="_blank">12851868</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9826720">
<a name="9826720"></a>Wagner UG, Koetz K, Weyand CM, Goronzy JJ. Perturbation of the T cell repertoire in rheumatoid arthritis. <i>Proc Natl Acad Sci U S A</i>. 1998;95(24):14447-14452. doi:10.1073/pnas.95.24.14447<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/9826720/pubmed" id="9826720" target="_blank">9826720</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31436026">
<a name="31436026"></a>Ward MM, Deodhar A, Gensler LS, et al. 2019 update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. <i>Arthritis Care Res (Hoboken)</i>. 2019;71(10):1285-1299. doi:10.1002/acr.24025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/31436026/pubmed" id="31436026" target="_blank">31436026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30346529">
<a name="30346529"></a>Weizman AV, Nguyen GC, Seow CH, et al. Appropriateness of biologics in the management of Crohn's disease using RAND/UCLA appropriateness methodology. <i>Inflamm Bowel Dis.</i> 2019;25(2):328-335. doi: 10.1093/ibd/izy333.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/30346529/pubmed" id="30346529" target="_blank">30346529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19416947">
<a name="19416947"></a>Williams EL, Gadola S, Edwards CJ. Anti-TNF-induced lupus. <i>Rheumatology (Oxford)</i>. 2009;48(7):716-720. doi:10.1093/rheumatology/kep080<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/19416947/pubmed" id="19416947" target="_blank">19416947</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16447241">
<a name="16447241"></a>Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. <i>Arthritis Rheum</i>. 2006;54(2):628-634. doi:10.1002/art.21568<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/16447241/pubmed" id="16447241" target="_blank">16447241</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24185311">
<a name="24185311"></a>Yanai H, Shuster D, Calabrese E, Mlynarsky L, Tumuluri S, Cohen RD. The incidence and predictors of lupus-like reaction in patients with IBD treated with anti-TNF therapies. <i>Inflamm Bowel Dis</i>. 2013;19(13):2778-2786. doi:10.1097/01.MIB.0000435435.91988.b6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/adalimumab-including-biosimilars-pediatric-drug-information/abstract-text/24185311/pubmed" id="24185311" target="_blank">24185311</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Celltrion.1">
<a name="Celltrion.1"></a>Yuflyma (adalimumab) [prescribing information]. Jersey City, NJ: Celltrion USA Inc; September 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Yuflyma.1">
<a name="Yuflyma.1"></a>Yuflyma (adalimumab) [product monograph]. Toronto, Ontario, Canada: Celltrion Healthcare Canada Limited; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Yusimry.1">
<a name="Yusimry.1"></a>Yusimry (adalimumab-aqvh) [prescribing information]. Redwood City, CA: Coherus BioSciences Inc; September 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 13077 Version 455.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
